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ABSTRACT

COST OF CARE FOR HOSPITALIZED PATIENTS WITH PULMONARY
MYCOBACTERIAL DISEASES IN THE UNITED STATES
Mary Elizabeth Wells Allen
November 30, 2016
Background: Pulmonary mycobacterial diseases describe both
tuberculosis (TB) and nontuberculous mycobacteria (NTM). Few data are
available measuring the cost burden of mycobacterial diseases on the
national level. The purpose of this study was to evaluate the cost burden
and measure emerging trends in hospitalization of pulmonary TB and
NTM in the US from 2001 through 2012.
Methods: This study was a retrospective community based cost analysis
of hospitalized patients with a principal diagnosis of pulmonary
mycobacterial diseases from 2001 through 2012. Data for pulmonary TB
and NTM were retrieved from the Healthcare Cost and Utilization Project
(HCUP), US Department of Health and Human Services. The statistical
significance of observed trends of NTM and TB national hospital costs
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was calculated using Poisson log-linear regression.
Results: A total of 20,049 hospital admissions were reported for
pulmonary NTM and 69,257 for pulmonary TB in the US from 2001
through 2012. The total associated cost of these admissions was
$903,767,292 for pulmonary NTM and $2,078,113,317 for pulmonary TB.
During the study period, the national hospital costs of pulmonary NTM
increased at a statistically significant rate in the US over each year
(P=0.001). However, no such increase was found for national hospital
costs of pulmonary TB.
Conclusion: The national hospital cost of NTM management is
increasing. These results emphasize the importance of continued
research in pulmonary NTM in order to improve current guidelines in
prevention and treatment strategies.
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INTRODUCTION
Mycobacterial diseases describe the infectious processes caused
by one of many pathogens from the Mycobacteriaceae genus. The most
notable of these pathogens is Mycobacterium tuberculosis (TB), which
remains an important worldwide public health challenge. Another
important pathogen is Nontuberculous mycobacteria (NTM) which has
become an emerging public health problem. Both TB and NTM have
many clinical presentations, but the most common manifestation of
disease is pulmonary and both diseases manifest with similar
symptomology. Both diseases are also associated with significant
morbidity and mortality. Despite similarities, TB and NTM differ
dramatically in terms of contemporary public health challenges. Recent
advances in laboratory diagnostic techniques, the improvement of
treatment regimens, and improvements in disease surveillance and control
have allowed many developed countries to reduce the burden of TB. This
is the case in the US in which TB related mortality has been in decline.
Still, major challenges in TB care persist, and include the drug resistance
and co-infection with HIV disease. Although TB in the developed world
still impacts key populations, the global TB epidemic which have been
shown to disproportionately affect developing countries in Asia and Africa.
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NTM, however, represents an emerging public health problem with
increasing incidence and associated death rates that are projected to
continue to increase in coming decades. The cost of care for both
diseases is likely to reflect these challenges. The purpose of this study is
to evaluate the cost burden of pulmonary TB and NTM in the US as well
as to identify emerging trends using hospitalization data obtained from the
Healthcare Cost and Utilization Project (HCUP), a database from the US
Department of Health and Human Services. Data was collected between
the years 2001 and 2012 in order to show changes over time for both
diseases. The goal of this study was to demonstrate the clinical
importance and cost of managing mycobacterial diseases in order to
identify important considerations for future research as well as provide
important data that could serve as decision support for the formation of
health policy.
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CHAPTER 1: OVERVIEW OF MYCOBACTERIAL
DISEASE
Mycobacterium is defined as any one of the variety of both
pathogenic and nonpathogenic organisms that are from the genus of the
Mycobacteriaceae family. Currently consisting of nearly two hundred
currently identified species, mycobacteria have several important and
distinct characteristics. For starters, mycobacterium species are aerobic,
which means these organisms rely on oxygen for survival. This also has
important clinical implications for mycobacterial disease, which describes
any disease process caused by pathogenic mycobacterium organisms.
Pulmonary disease is the most common manifestation of mycobacterial
diseases given the high availability of oxygen in the lungs, and symptoms
appear the same in most cases regardless of the pathogen. However,
mycobacterial diseases can occur at most any location. Mycobacterium
organisms are slow growing, which impacts diagnostics given that cultures
sometimes take weeks to form colonies in a laboratory setting. The slow
growth of mycobacteria also has important clinical implications that can
lead to a sometimes mild and chronic form of disease. Mycobacterium
species are characterized by particularly thick cell walls that contribute to
survival in different environments as well as resistance to many antibiotic
3

therapies. Drugs used to treat mycobacterial diseases often involve
alternative pathways of cell entry, as cell wall penetration is a common
mechanism of action for many types of antibiotics. This results in fewer
therapeutic options available to treat mycobacterial disease, and therapy
is much longer in duration as compared to most other infections. Also, the
cell wall is constructed of a waxy, lipid material that repels the dyes used
in Gram staining resulting in a distinct appearance referred to acidfastness. This feature is unique to mycobacteria and helps support
diagnostics given the slow culture growth of these organisms.
Mycobacteria are referred to as bacillus, which is a term used to describe
rod-shaped organisms. Their unique appearance also contributes to the
recognition of mycobacteria in a laboratory setting.1,2 Infections caused by
mycobacterium species tend to be chronic, difficult to diagnose, involve
long complicated treatment courses, and represent a significant source of
morbidity and mortality in the US and the world.3
Mycobacterium tuberculosis
Mycobacterium tuberculosis (TB) is the most common
mycobacterium species that causes disease in humans. Discovered by
German scientist Robert Koch in 1882 as part of the M. tuberculosis
complex of organisms, TB includes diseases caused by M. africanum, M.
bovis, M. microti, and M. canett, and M. tuberculosis.4 TB represents an
important public health challenge on a global scale.
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History
TB has been believed to be a source of human disease for
thousands of years, but the origin and pathogenic history of TB is not well
understood. Several DNA studies of remains from humans and animals
have attempted to piece together the epidemiological history of disease in
world populations as well as the genetic evolution of M. tuberculosis
organisms. For example, TB has been isolated in human remains
collected from thousands of years ago from locations on both sides of the
Atlantic Ocean. Evidence of the presence of TB in the western
hemisphere consists of the discovery of the disease in a human mummy
discovered in Peru from around 6,000 years ago.5 This finding was similar
to those isolated from Egyptian mummies.6 Another discovery was made
in the remains of an extinct bison estimated to be around 17,000 years old
in North America. Identification of DNA fragments was conducted using
the spoligotyping technique with direct DNA sequence determination,
suggesting that cattle may have been one of the earliest vectors for
disease transmission.7 In the eastern hemisphere, a study of samples
obtained from ancient Syria identified the presence of TB in human
remains; however, TB was not isolated from animal remains from the
same site. This evidence suggests the presence of human disease prior
to animals following domestication.8 Additionally, several studies have
identified TB in the remains of humans from Europe, Asia and Africa.
Many of these reports and subsequent DNA analyses can be found in the
published work from Albert Zink and colleagues. In numerous studies,
5

Zink has taken mummified and skeletal remains from different time
periods and compared them with genetic material of TB obtained from
present day samples. Comparing historical samples from southern
Germany (1,400–1,800 AD), Hungary (600–1,700 AD),9,10 and Egypt
(3,500–500 BC), Zink and researchers were able to further characterize
mycobacterial DNA samples obtained from ancient Egypt.11
In the more recent history, TB is well described as a source of
significant morbidity and mortality for centuries in Europe. Referred to by
a number of names including consumption, the robber of youth, and the
white plague, the disease was well described in both medicine and
literature of the time. Doctors, writers and even poets described the
characteristic features of the disease that included thin bodies secondary
to wasting, pale complexion, and the association of the disease with the
youth.12 In the seventeenth century, infection rates in London, England
were reported at 1,000 per 100,000 people per year.13 During the
eighteenth and nineteenth centuries, TB rates increased charactering the
disease as an epidemic in Europe that disproportionately affected the
poor. Although history reports incidents of the wealthy becoming infected
with the disease, they were afforded the option to travel to more suitable
climates, comforts and access to remedies. These options were not
available to the poor, who were likely confined to substandard living
conditions and subject to poor nutrition. These factors amplified the
impact of the disease process in this population and most likely
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contributed to poor outcomes and an increase in death rates.14 By the
nineteenth century, TB was attributable to 25% of all mortality in Europe.
Interestingly, infection rates declined at the turn of the twentieth century
prior to the discovery of anti-TB drugs. This decrease in TB infection rates
is believed to be a result of improvements in standards of living in cities,
which includes housing, nutrition and rising income.15 As a result of the
advent of anti-TB drugs coupled with public health policies focused on
treatment and prevention, TB in the twentieth century became irrelevant.
In fact, some experts of the time believed that TB could be eradicated like
other infectious diseases such as smallpox.16
At the close of the twentieth century, TB reemerged as a major
global epidemic. Among the factors contributing to the sharp resurgence
in TB rates was the worldwide HIV/AIDS pandemic coupled with the onset
of drug resistance. TB having become a recurring global health crisis
stimulated renewed interest in research and development in many areas
of the disease, resulting in recent advancements in diagnostics,
treatments, and improving the understanding of clinical and nonclinical
factors impacting human disease.17 However, because mortality rates
sharply declined for a time, fewer resources were diverted to new drug
development, diagnostics and vaccine studies for several decades. As a
result, the medical community continues to rely upon outdated therapies
and diagnostic technology in care settings in both developed and low
resource countries, leaving much of the world ill equipped to address
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emerging needs.18,19
Clinical Features
The natural history of TB infection begins with exposure followed by
the onset of latent disease. Latent TB describes the colonization of the
organism in body. Latent TB rarely presents with symptoms as the
mycobacterial pathogens remain dormant until an opportunity presents
itself to overtake a weakened immune system and multiply. It is common
for active infection to occur years later following a major change to the
host’s health status, particularly the immune system. However, the
activation of disease sometimes occurs for no known reason, resulting in
progression from latent to active disease being sometimes unpredictable.
Screening for latent disease can be part of an effective prevention strategy
by treating latent infection thus preventing the activation of disease.
Treating latent disease can also be an important strategy in reducing
further transmission. Testing for dormant infection can be done using the
tuberculin skin test (TST) or blood assay tests including the QuantiFERON
and T-SPOT.20,21
The next phase in TB is the activation of disease. Pulmonary TB
is the most common manifestation of disease with classic symptoms
including chronic productive cough, hemoptysis, fevers and/or chills, night
sweats, and weight loss. However, TB infection can occur at virtually any
position in the body. Atypical presentations, which is commonly referred
to as extrapulmonary TB, describes any presentation of TB infection
8

outside of the lungs.22 In these cases, symptomology can be diverse with
many symptoms having been described in the medical literature for each
site of infection. Most common extrapulmonary TB sites of infection
include lymphadenitis, pleural space, septic arthritis, osteomyelitis, central
nervous system, abdomen, and disseminated disease. Extrapulmonary
TB has become more common since the beginning of the HIV/AIDS
pandemic, with immunosuppression associated with advanced AIDS being
a primary risk factor. In fact, more than half of AIDS patients develop
extrapulmonary TB. Further, the management of extrapulmonary TB in
HIV infected hosts can present treatment challenges given the higher
likelihood of drug-drug interactions, but treatment response in HIV infected
hosts seems overall favorable without any measurable increased risk of
infection relapse.23
Host factors play a critical role in susceptibility to infection as well
as disease presentation, some of which are not well understood. Young
adult males, for example, have been shown to have a higher likelihood of
developing TB than other age groups and more so than females.
Healthcare workers are another important risk group given their much
higher likelihood of exposure, especially those working with populations
with higher TB prevalence or in specialty clinics in which TB patients are
being treated. Other host factors can be explained by immune
suppression.24 Activation of TB can occur secondary to several health
conditions and diseases that suppress the immune system, the use of
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certain drug therapies that suppress the immune system as part of cancer
treatment, post-transplant therapy or immune modulation therapy such as
antitumor necrosis factor-α (TNF-α) drugs commonly used to treat autoimmune diseases. Also, the presence of several underlying diseases are
a common facilitator of active TB infection in many parts of the world such
as pulmonary diseases, diabetes mellitus,25 and other conditions that have
been shown to affect the immune system. Behavioral factors can also
play an important role such as diet and malnutrition, alcoholism, and
smoking tobacco, the latter of which the World Health Organization (WHO)
attributes to 20% of TB cases.26,27 Emerging science has also pinpointed
genetic susceptibility factors, some of which are being explored for the
purpose of developing personalized therapies and vaccines.28,29
Transmission
The transmission patterns of TB have remained a point of inquiry in
historical and current studies. The transmission of disease person to
person is well described. Although the highly contagious nature of TB
pathogens allows the disease to be transmitted with only small amounts of
airborne respiratory fluids propelled through the air via coughing and
sneezing, the reasons TB is transmitted to some and not others following
exposure is not established.32 Also, transmission pathways between
humans and animals, and vice versa, are not well understood. Historical
studies have sought to understand this pathway in ancient populations in
which evidence of disease was identified in both animal and in human
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populations, but the transmission from one to another following the
domestication of animals in prehistoric populations has not been fully
documented. More recent history demonstrates a strong relationship
between human and animal populations. A study published by Davies
traces TB reports in nineteenth century slaughterhouses, cow’s milk
during Victorian times, and possible transmission from cows to humans
during urbanization through infected milk. In fact, this transmission
pathway has been described as an important facilitator of the resurgence
of disease in the eighteenth and nineteenth centuries held by several
researchers, proposing that TB infected milk in Great Britain was
responsible for the epidemic beginning in the Victorian Era through World
War II.33,34 Further, Davies estimates TB in the food supply remains an
important risk in developing countries, particularly when food production
occurs within the bounds of densely populated cities.35 Among the M.
tuberculosis complex of organisms, M. bovis has been the organism most
often associated with disease in cattle. Although few cases of M. bovis
have been identified through diagnostic methods, some researchers
suspect this number is underreported given limitations in diagnostic
techniques in correctly sampling specimens. Regardless of the potential
clinical importance of M. bovis, M. tuberculosis remains the most
important cause of TB infection worldwide.36
Additionally, some have questioned the animal to human and
human to animal transmission pattern of other M. tuberculosis complex
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organisms as well as the role of other animal species. Several case
reports are present in the literature of TB having been found in companion
animals, but the transmission pathway remains unclear. A case report of
a nine-year-old pet dog was found to have had tuberculomas in the heart,
which is a rare manifestation of TB in humans and presumably animals.
Case reports generally describe the presentation of disease as pulmonary
or lymphadenopathy. This report notes that TB infection was not present
in any members of the household.37 Another case study identified TB
infection in a companion dog using Polymerase chain reaction (PCR) and
spoligotyping at necropsy. This study noted that TB infection was not
found in household members, but the diseases may have been
transmitted from the dog to veterinary personnel during necropsy.38 A
recent case study from Brazil described TB infection and mortality in a pet
dog following the occurrence of TB in the household.39 Another Brazilian
case study noted disseminated disease in a 12-year-old pet dog
diagnosed following the death of one the members of her household
secondary to pulmonary TB. The dog in question was noted to have been
in particularly close contact with the diseased, having been observed
licking respiratory secretions during his illness.40
More collaborative and multi-disciplinary research is needed in
order to better understand the scope of animal to human transmission and
prevent the transmission of disease through medical and public health
intervention. The future of research in this area will depend upon
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improvements in diagnostic techniques, application of more advanced
discriminatory genotyping tools, and collaboration with veterinary
researchers.41
Further, environmental transmission of TB has not been ruled out
as a possibility given the presence of pathogenic samples identified in soil
and water samples. In a study conducted in metropolitan Tehran, TB was
identified in 11 of 800 soil samples and 71 of 700 water samples collected.
Following six months after sampling, 36% of samples from soil and 8.4%
of samples from water remained culturable. This finding implies that TB
organisms remain viable in environmental sources for extended periods of
time, increasing the possibility of transmitting the disease to human and
animal populations.42
Diagnosis
The process of diagnosing active TB begins with the evaluation of
symptomology and host factors before proceeding to radiological and
microbiological findings. Pulmonary TB has classic symptoms and
characteristic cavitary lesions usually appearing in the upper lobes of the
lungs visible on radiological exam.43 However, abnormal host factors can
undermine classic disease appearance in the lungs. Host factors also are
an important indicator of the presentation of extrapulmonary disease.44
Laboratory findings represent another important factor in disease
diagnosis. The diagnosis of TB usually involves a two-step process:
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smears that determine the presence mycobacterium species and follow up
cultures or molecular testing that are used for species identification.
Ideally, a third step in the process should include drug susceptibility
testing (DST).
The process begins with smears, which involves staining clinical
samples in order visualize appearance of the organism. Characteristic
features of mycobacterium species are acid-fastness due to the unusual
thick and lipid cell wall of the organism. Also, mycobacterium species are
rod shaped, which would be visualized following smear staining. A
number of smear methods are currently used. Fluorescence microscopy
represents one of the first and most common laboratory techniques. This
method involves the use of flourochrome dyes on the samples along with
halogen or high-pressure mercury vapor lamps in order to visualize the
results. However, the use of fluorescence microscopy relies on reliable
access to electricity and related infrastructure, which is not realistic in
some settings. Conventional smear microscopy using the Ziehl-Neelsen
technique has been the most common method used in low to middle
resource countries for this reason. Although this method has been well
proven and represents a cost effective smear test in many care settings,
smear microscopy requires high quality samples.45 Also, the sensitivity
and specificity decrease when diagnosing extra-pulmonary disease and
this method is less proven in pediatric populations and in patients with
compromised immune systems.46,47
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Because smears only have the capacity to identify mycobacterium,
follow up tests are necessary for species identification. Mycobacteria
cultures can be performed using liquid or solid media. Liquid cultures
involve an automated process with a relatively quick turn around time with
high sensitivity rates. However, the risk of contamination is higher for
liquid culture due to the presence of mycobacterium species in water.48
Polymerase chain reaction (PCR) is an alternative testing method using a
DNA amplification technique.49 The major advantage of PCR is results
are reported usually within a couple of days. High-performance liquid
chromatography (HPLC) is another molecular method that has been used
for identifying mycobacterium species. Having been first introduced in the
1960s, HPLC has been standard procedure at the CDC Mycobacteriology
Reference Laboratory since 1990.50,51 Among the major advantages of
HPLC is that species identification can be as immediate as a few hours.
However, HPLC relies on high quality specimens and requires highly
trained laboratory personnel to perform the procedure. Further, this
technique is expensive as compared to cultures. This has important
implications for use in many low resource, high burden TB countries. In
many of these clinical settings, laboratory methodology relies only upon
smears, and follow up studies involving species identification and drug
susceptibility testing is not done.52 Also, cultures and molecular testing
may be done in cases of negative results following smear staining when
mycobacterial diseases are highly suspected. All laboratory techniques
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rely on quality specimens, and have differing capabilities depending on the
specimen source. Given that pulmonary infection is the most common
manifestation of mycobacterial disease, laboratory testing techniques
generally have a better yield using respiratory samples. Also, invasive
collection techniques for respiratory samples such as bronchoscopy are
considered higher quality specimens.53,54
The final step that follows smears and species typing is drug
susceptibility testing (DST). DST describes the process of testing
laboratory isolates against common antimicrobial agents in order to
optimize therapy. This step is especially important in cases in which
resistant disease is suspected following the reconciliation of patient
characteristics that imply a risk for resistant disease. These factors may
include a patient history of treatment failure or having been born or visited
regions of the world in which drug resistance is common.55 Another
consideration for DST involves the risk of infection from other
mycobacterium species.
However, diagnostic challenges persist for many reasons. First,
the slow growth of mycobacterium organisms often requires therapy
initiation in suspected cases prior to official diagnosis. In some cases,
patients may be treated improperly for another disease process such as
community-acquired pneumonia, which represents inappropriate antibiotic
and healthcare resource use. Also, the slow development of new
diagnostic technology remains a persistent challenge. Given the low
16

prevalence of TB until the end of the twentieth century when global
resurgence occurred, research and development in TB laboratory
methodology all but halted along with drug therapies and vaccine studies.
Only recently has research and development in the area of TB produced
results that have improved laboratory methods and made available new
treatment options. The challenges this creates involve not only
diagnostics, but also therapy choice. Slow and difficult microbiological
testing often results in the initiation of empiric therapies based on the
clinical suspicion of clinicians in terms of organism and drug susceptibility
as confirmation of infection may occur weeks later.56,57,58
Despite the numerous options for laboratory studies, access to
many of these techniques is unavailable in many care settings. A recent
report by UNITAID, an organization developed to address common global
health concerns in a cost effective approach, is hopeful regarding the
future of diagnostic technology. First, the recent introduction of Xpert®
Mycobacterium TB/Rifampin (MTB/RIF) has been an important
development that has been encouraging for the future availability of new
technology. Xpert MTB/RIF is a new diagnostic technique that replaces
multi-step process of smears, cultures and susceptibility testing to first line
drug rifampin is encompassed in one test cartridge. In 2014, more than
10 million Xpert MTB/RIF test cartridges were purchased by the public
sector in 116 of the 145 countries eligible for concessional pricing.
UNITAID reports that, in addition to Xpert MTB/RIF, a pipeline of
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molecular diagnostics or nucleic acid amplification tests are in
development from over 50 companies. However, the report noted that
new diagnostic methods will struggle to reach scale. Also, other
challenges including long treatment courses persist with no obvious new
regimens with shorter duration of therapy in the pipeline. UNITAID also
emphasized the importance of developing diagnostics that do not rely on
the availability of sputum samples for select situations, particularly for the
diagnosis of disease in pediatric populations. Given that TB
disproportionately affects low resource countries in greater prevalence,
UNITAID also raised concerns regarding the availability of new
technologies to low resource countries specifically.59 Other reports
examining the future landscape of TB diagnostics have raised similar
concerns regarding the availability and affordability of TB diagnostic
technology to the countries in greatest need.60
Treatment
Treatment for TB presents a number of important challenges.
First, anatomical properties of mycobacterium species including an
abnormal thickness of the cell wall as compared to other bacterial
organism makes TB resistant to most antibiotics. This leaves few
treatment options relative to the several classes of currently available
antibiotics. Also, standard treatment for active infection involves a
regimen ranging from six months to nine months in duration, or four
months following culture conversion. During treatment courses, patients
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must make regular visits to providers to ensure medication compliance as
well as measure clinical response. Providers must also prevent
treatment interruptions or abandonment by ensuring patients maintain the
ability to be compliant, or transfer treatment in the event of relocation.
The failure of patients to complete treatment has important implications
for the continued transmission of disease as well as the facilitation of
drug resistance. Another important factor is TB treatment is the
management of drug therapies relative to adverse reactions and
comorbid conditions. Long treatment courses compound the risk of side
effects and adverse events. As a result, standard of care involves regular
blood monitoring in order to identify toxicity and other potentially serious
side effects. Also, TB drugs have the potential to interact with treatment
for several comorbid conditions, which also represents an important
aspect of medical management. For these reasons, providers must be
vigilant in maintaining patient contact during treatment courses. This can
be particularly challenging when appropriate treatment requires
compliance from patient populations known for incompliance.
Standard treatment for TB may include any of the following firstline drugs: isoniazid, rifampin, rifabutin, rifapentine, pyrazinamide, or
ethambutol. Table 1 outlines the recommended therapy for adults ages
15 years and older with active infection based on expert guidelines
published in a joint report by the American Thoracic Society/Centers for
Disease Control and Prevention/Infectious Diseases Society of
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America.61
Table 1: Recommended Therapy for Drug Susceptible TB
First-Line	
  
Preparation

Therapies	
  

Daily
Dose

15 mg/kg
(900 mg)

3x/week
Dose

Tablets (50
mg, 100 mg,
300 mg; elixir
(50 mg/5 mL);
aqueous
solution (100
mg/mL) in IV
or intramuscular
injection

Rifampin	
  

Capsule
(150 mg,
300 mg);
powder may
be
suspended
for oral;
aqueous
solution for
IV injection

10 mg/kg
(600 mg)

10 mg/kg
(600 mg)

10 mg/kg
(600 mg)

Rifabutin	
  

Capsule
(150 mg)

5 mg/kg
(300 mg)

5 mg/kg
(300 mg)

5 mg/kg
(300 mg)

Tablet (150
mg, film
coated)

15mg/kg
(900 mg)

2x/week
Dose

Isoniazid	
  

Rifapentine	
  

5 mg/kg
(300 mg)

Weekly
Dose

10 mg/kg
(continuati
on phase)
(600 mg)

Pyrazinamide	
   Tablet (500
mg, scored)

Weightbased
dosing

Ethambutol	
  

Weightbased
dosing

Tablet (100
mg, 400 mg
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15 mg/kg
(900 mg)

For patients with resistance or toxicity to first line agents, TB
treatment courses may consist of a host of other less effective or less
proven drug options. These regimens may be used following a treatment
failure, resistance reported following DST performed at diagnosis, or
following a clinical review of medical history that is suspicious for drug
resistance. Factors such as recent travel from regions with high
resistance patterns or medical history with previous regimens and/or
treatment failures may impact choice in therapy. Table 2 shows a
complete grouping of anti-TB therapy.62
Table 2: Anti-TB Therapy Options

Group 1: First line (Use all possible drugs)
Isoniazid

Ethambutol

Rifampin

Pyrazinamide

Group 2: Flouroquinolones (Use only one, agents share genetic targets)
Levofloxacin

Moxifloxacin

Ofloxacin
Group 3: Injectable (Use only one, agents share similar genetic targets)
Capreomycin

Amikacin

Kanamycin

Streptomycin

Group 4: Less effective second line drugs (Use all possible drugs if
necessary)
Aminosalcylic acid (acid salt)
Group 5: Less effective or less proven drugs (Use all necessary drugs
if there are less than four from the other groups)
Bedaquiline

Linezolid

Delamanid

Imipenem/cilastatin

Clofazimine

Meropenem

Amoxicillin with clavulanate

Clarithomycin
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Drug resistance is a common problem affecting the treatment of
many infectious diseases and is most commonly a consequence of
overuse and inappropriate use of common drug therapies. In TB care,
drug resistance is among the most important challenges, which is a
worldwide problem affecting both developed and underdeveloped
countries. Multi-drug resistant TB (MDR-TB) is characterized by
resistance to first line drugs isoniazid and rifampin. Extreme-drug
resistance TB (XDR-TB) is characterized by resistance to first line drugs
isoniazid and rifampin, in addition to any fluoroquinolone and one of the
following three injectable second-line drugs: amikacin, kanamycin, and
capreomycin. Scant reports of totally drug resistant TB (TDR-TB) have
been made in which strains have demonstrated resistance to all drugs
used for TB treatment.63,64,65
Drug resistance creates greater challenges in the developing world
for several reasons. First, standard laboratory techniques are often limited
in resource scarce countries, so susceptibility testing may not be standard
or available. In these cases, resistance may be diagnosed following a
treatment failure, which represents more cost to the healthcare system as
well as a longer treatment course and a greater risk of adverse events.66
Also, second line therapies may be limited and more costly, which is
particularly challenging when managing care in underdeveloped countries
with limited resources. According to the WHO, 480,000 cases of MDR-TB
were reported in 2014 worldwide. An estimated 10% of MDR cases were
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XDR-TB. More than half of all resistant cases were in China, India and
Russia.67
Epidemiology
The WHO characterizes TB as a worldwide epidemic with cases
having been documented in almost every country around the world. In
2014, nearly 10 million people developed active disease and 1.5 million
died as a result. An estimated one third of the world’s population is
currently infected, most of which with latent disease.68 Public health policy
in the US and abroad has focused on treatment and disease surveillance
of pulmonary TB. These efforts coupled with improvements in
diagnostics, treatment, and prevention have reduced the public health
impact of TB in the US and other western nations. In the underdeveloped
world, TB remains an important public health challenge.
The relationship between TB and poverty is well described.
Contributing factors driving the transmission of TB is these settings
include high population density along with malnutrition, concomitant
medical conditions that affect immunity, and behavioral factors such as
smoking and alcohol use. For these reasons, the burden of new cases
falls disproportionately on poor countries located in Southeast Asia,
Western Pacific and Africa. In fact, 80% of new cases occurred in the
same 22 countries in 2014, including South Africa, Nigeria, India,
Pakistan, Indonesia and China to name a few. Also, over 95% of TB
related deaths occur in low to middle resource countries.69 In many of
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these countries, HIV/AIDS represents a critical factor predisposing large
segments of the population to TB infection. According to some reports,
HIV/AIDS is believed to be responsible for a three to five times increase in
the incidence of TB infection in high HIV prevalence countries located in
sub-Saharan Africa.70,71 TB infection in HIV/AIDS infected hosts often
presents with more aggressive disease as well as extrapulmonary
involvement. In fact, the atypical presentation of TB occurs in more than
half of patients with advanced HIV/AIDS. Co-infected hosts also are more
likely to experience complications as well as medication interactions, and
TB related mortality in this population is a common outcome.72 A 2014
WHO report claims that one in three deaths of HIV positive patients can
be attributed to TB, emphasizing the particularly devastating role HIV
plays in TB in countries with high HIV/AIDS prevalence. The WHO also
reports that HIV infected patients are 20 to 30 times more likely to
progress to active disease from latency as compared to the general
population.73 The impact of HIV/AIDS is easily illustrated in the figure
below outlining a comparison of worldwide TB incidence showing data
from high-income countries verses other world regions including a
stratification of data from Africa separately reported based on high
HIV/AIDS prevalence.74
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Figure 1: Global TB incidence 1990-2008
The availability of current diagnostic methods and anti-TB therapies
has been one of the most important developments in addressing TB as a
worldwide global health concern. An estimated 43 million lives were
saved between the years 2000 and 2014 as a result of TB diagnostics and
treatment.75
Nontuberculous mycobacteria
Nontuberculous Mycobacterium (NTM) describes a group of
organisms ubiquitous to the environment that have been associated with
disease in both humans and animals. Recent reports indicate that NTM is
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an emerging pathogen in many parts of the world, but particularly in
developed countries in North America, Europe, Asia and Australia.76 In
the US, NTM rates are sharply rising in prevalence, particularly in the
older population of adults.77,78 NTM is a source of significant morbidity in
the US. Patients with NTM infection require extensive healthcare
resources including hospitalizations, frequent outpatient visits, and
complicated therapy with associated treatment challenges. NTM is also
an increasingly important cause of mortality in the US.79,80,81
History
NTM was first identified in the 1950s by Ernest Runyon. A botanist
who published his findings in 1959, Runyon categorized the newly
discovered species based on growth rates, colony morphology, and
pigmentation.82 Prior to Runyon’s discovery, the history of NTM as a
human pathogen remains unknown.
The Runyon system categorizes NTM species into 2 primary
categories: slow growing and fast growing. Slow growing NTM are further
organized into three subcategories based on the pigment production.83
The contemporary Runyon classification system consists of a considerably
higher number of NTM species as more continue to be discovered.
Currently, more than 150 species of NTM have been identified.84,85 As
advances in laboratory methods have evolved in recent years, the Runyon
classification system based on growth rates and pigment production has
become less relevant. New rapid culturing techniques including DNA
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probes and high-pressure liquid chromatography do not abide by the
Runyon classification system. Also, the Runyon classification does not
reflect unique clinical features of each pathogenic NTM species.86,87
Table 3: Runyon Classification of NTM Species

Slow Growers (Colonies may take
up to 8 weeks to form)

Runyon

1

2

Fast
Growers
(Colonies
grow within
5 days)
3

4

Classification Photochromogens Scotchromogens Nonchromogens Rapid Growers
Pigment

Produces
yellow-orange
pigment
following
exposure to light

Produces
yellow-orange
pigment in light
and dark

Produces no
pigment

Produces no
pigment

Species

M. kansasii, M.
marinum, M.
asiaticum, and
M. simiae

M. gordonae
and M.
scrofulaceum

M. avium, M.
intracellulare,
and M.
ulcerans

M. fortuitum, M.
peregrinum, M.
abscessus, M.
chelonae, and
M.
thermoresisibile

Despite recent advances in NTM research, this field of
mycobacteria remains understudied. A lack of support in the form of
international grants as suggested by one study is responsible for the
deficit in clinical and basic science research in the area of NTM.65 In the
US, only 5 of the 228 grants available from the National Institute of Health
(NIH) include sponsorship for research in NTM.88 Therefore, the field of
NTM research represents an important unmet need relative to the rising
epidemiology and cost in the US.
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Clinical Features
The majority of NTM cases manifest in the form of pulmonary
disease, as is the case with TB infection. Extrapulmonary NTM, or NTM
cases that present in the form of infection outside of lung disease, is
estimated to occur in the US in up to 10% of cases.89 NTM infections
have the potential to involve any site in the human body. Atypical
presentations cause a number of infections including lymphadenitis, septic
arthritis, osteomyelitis, skin and soft tissue infections, and disseminated
disease.90,91,92
NTM disease can be caused by a number of different species as
many are considered pathogenic to humans. Currently, more than 150
species of NTM have been described, with new ones being routinely
discovered.9 The most common NTM pathogens associated with human
infection are the species associated with Mycobacterium avium complex
(MAC). MAC describes infections caused by two primary organisms, M.
avium and M. intracellulare, as well as any one their genetically similar
subspecies. In the US, MAC accounts for up to 80% of pulmonary NTM
infections according to some reports.93,94,95 Other reports classify more
than half of NTM cases in the US as MAC, and global figures are only
slightly less. Molecular sequence data have identified 10 subspecies of
MAC as listed in the table below.96
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Table 4: MAC Subspecies Organisms

Mycobacterium Avium Complex Subspecies Organisms
M. avium

M. intracellulare

M. homisissuis

M. bouchedurhonense

M. silvaticum

M. timonense

M. paratuberculosis

M. arosiense

M. colombiense

M. marseillense

Although MAC represents one of the most important causes of
NTM disease, many NTM species have been associated with human
diseases. See Table 5 for a listing of common NTM pathogens that have
been strongly associated with infection in humans.97
Table 5: Common NTM Human Pathogens

Common NTM Human Pathogens
M. avium complex (MAC)

M. porcinum

M. kansasii

M. conceptionense

M. porcinum

M. phlei

M. lentiflavum

M. austroafricanum

M. monacense

M. elephantis

M. abscessus

M. parascrofulaceum

M. thermoresistibile
According to a recent study outlining the epidemiology of NTM
species as a cause of pulmonary disease, the geographical variation of
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NTM varies considerably between sample data from six continents.
Overall, MAC still represents the most common cause of pulmonary
infection. See the figures below for a representation of the most common
NTM species associated with disease in humans based on global
averages as well as figures for North America. These data demonstrate
both the clinical importance of MAC on both a global scale and in North
America, as well as the other NTM pathogens as important causes of
disease. Also, these data emphasize the importance of rapidly growing
mycobacteria (RGM) as a cause of disease in North America.98 The most
common RGM species are M. fortuitum, M. abscessus, and M chelonae.99

MAC	
  
M.	
  kansasii	
  
M.	
  xenopi	
  
M.	
  malmoense	
  
M.	
  gordonae	
  
Other	
  

Figure 2: Global Average of NTM Species as a cause of disease
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Distribution	
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M.	
  kansasii	
  
M.	
  xenopi	
  
RGM	
  
M.	
  gordonae	
  
Other	
  

Figure 3: NTM Species as a cause of disease in North America
The amount of NTM to which one has been exposed has also been
shown to predict the likelihood of disease. However, the infectious dose
for NTM infection remains unknown but current estimates demonstrate
this at anywhere between 10-102 units.100 In a mouse model, M. ulcerans
infections identifiable by swelling occurred following exposure to a dose of
103-104 colony-forming units.101 This relationship has not been tested in
other NTM species and hosts, including humans.
As is the case with TB infection, host factors play a critical role in
susceptibility and clinical features of NTM infections. NTM is generally
considered opportunistic pathogens, which means that some level of
immunodeficiency or preexistent pulmonary disease usually exists in
patients with NTM.102 Four categories of well-defined susceptibility for
NTM infection have been identified.103 First, structural or preexisting
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pulmonary diseases such as cystic fibrosis, chronic obstructive pulmonary
disease (COPD), and bronchiectasis have been strongly associated with
the risk of developing many types of infectious lung diseases including
NTM.104 Second, patients with autoimmune disorders who are being
treated with antitumor necrosis factor-α (TNF-α) drugs are at risk for
developing NTM as well as many other opportunistic infections. Third,
HIV infected persons with AIDS are also at an increased risk for
developing NTM along with many other opportunistic infections. In fact, a
CD4+ T cell count of less than 50 cells/µL is associated with increased
risk of disseminated NTM disease. Fourth, patients with genetic
syndromes involving mutations in the interleukin-12 or interferon γ
pathways are also at risk for developing opportunistic infections including
NTM. Mutations in these pathways are associated with both autoimmune
disorders as well as immune suppression.105,106,107,108
In addition to these defined risk groups, solid organ transplant
recipients also have increased risk of NTM disease for several reasons.
Post-transplantation immunosuppressive therapy increases the likelihood
of clinical disease from environmental exposures.109 Also, underlying lung
disease in lung transplant patients place patients at a higher risk for NTM
infection during the pre-transplant period. Possible risk factors for the
recurrence of infection or the onset of new disease with NTM following
lung transplantation are immunosuppression and the development of
structural lung disease over time secondary to bronchiolitis obliterans
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syndrome.110,111
The risk of developing NTM is also strongly associated with
advanced age and the presence of comorbidities. This is believed to
contribute to the recent increase in cases in the US given the aging of the
population in the US, Canada and parts of Europe.112,113 Additionally,
nonsmoker elderly females with a slender body along with characteristic
features such as scoliosis, pectus defects, or mitral valve prolapse are
more prone to pulmonary NTM as compared to the general
population.114,115,116 In fact, NTM occurring in this population has been
termed Lady Windermere syndrome, and has a characteristic presentation
in the right middle lobe and/or lingua. Lady Windermere syndrome is
believed to be associated with voluntary cough suppression that causes
secretion accumulation creating an ideal place for growth of the NTM
organisms.117 Also, the elderly are more likely to be complicated to treat
given their increased likelihood to have comorbidities.
NTM infection is also more common in patients with specific
behavioral risk factors such as tobacco use, alcohol use and poor
nutrition.118 Despite well-defined risk groups, patients present with NTM
infection without obvious risk factors or the present of underlying
disease.119
Perhaps the most important host characteristic associated with
NTM infection is HIV/AIDS. Given that HIV is still commonly diagnosed in
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the US during late stages of the disease, the presentation of NTM in an
atypical host sometimes leads to an HIV/AIDS diagnosis.120 In fact, the
presence of NTM is considered by many experts to be an AIDS defining
illness, which is characterized by the presence of less than 200 CD4 Tcells that is often discovered following the diagnosis of opportunistic
infections, which often includes NTM infection.121
HIV/AIDS represents one of the most important risk factors for NTM
disease in patients of all ages including older populations. According to
the CDC, people aged 55 and older accounted for an estimated 24% of
the 1.2 million people living with HIV infection in the US in 2012.
The prevalence of HIV/AIDS in older populations can be attributed
to several factors. First, the effectiveness of HAART (Highly Active AntiRetroviral Therapy) in extending life spans of those infected with the virus
early during the HIV/AIDS epidemic have allowed HIV patients to age.123
HAART has extended lifespans well beyond expectation allowing many to
age into retirement with a disease that was once considered a death
sentence. The majority of this population is made up of the more
traditional at risk population of HIV positive adults including those who
acquired the disease through homosexual contact and IV drug use.
Newly diagnosed cases within this same age cohort have also
increased in recent years. An estimated 27% of patients over 50 years of
age accounted for new diagnoses of AIDS in 2013. The diagnosis of
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AIDS usually follows the identification of AIDS defining opportunistic
infections, which often includes a diagnosis of NTM disease. In older
populations, the CDC notes that late diagnoses are more common as
compared to younger populations.124 Among the unique risk factors for
this age group is a statistically significant increase of transmission through
heterosexual contact, which has specifically impacted the incidence of
HIV/AIDS in females over the age of 50. Given the low perceived risk of
heterosexual contact in this population, older adults are less likely to take
HIV/AIDS prevention measures.125 The CDC notes that clinicians treating
this population are less likely to suspect HIV/AIDS despite the presence of
clinical symptomology and older patients are less willing to share with their
care providers HIV/AIDS risk behaviors.126 Another important factor in the
prevalence of disease in the older populations is the estimated 80%
increase in erectile dysfunction treatment prescriptions in recent
years.127,128
Another important factor is HIV/AIDS transmission in older
populations, some scholars suggest that the aged are more likely to
seroconvert than their younger counterparts if exposed to the disease.
Among the explanations for this, age-related hormone production levels
decrease in the aged, resulting in the thinning of the vaginal and anal
mucosa. As a result, the likelihood of tearing during sexual contact
increases which allows a point of entry for the virus. Also, age-related
immunity function declines which leaves older adults more vulnerable to
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infection if exposed.129
Transmission
NTM species are environmentally ubiquitous organisms and
disease transmission is believed to occur primarily from the environment.
Having been isolated in various studies in soil and water sources,
understanding the factors contributing to the transmission of disease to
some hosts and not others remains an area of study. Emerging research
has demonstrated that NTM can be transmitted person to person. Also,
the relationship between humans and animals, and vice versa, is an
important area of future research. Finally, the food supply, primarily fish
living in water contaminated with NTM is another possible source of
transmission.
Reports from different parts of the world have identified various
species of NTM in environmental sources, including soil, dirt, household
water supplies, public water supplies, workplaces, and hospitals.130,131 In
a review surveying data from several Middle Eastern countries, NTM was
found in 619 environmental samples collected in Iran, Iraq, Turkey and
Saudi Arabia and the most common species noted in these isolates was
M. fortuitum.132 Several studies have also identified the presence of NTM
in soil and water samples. Soil samples collected from a forest located in
Finland identified the presence of NTM in 100% of the 47 samples.133 A
Japanese study tested a variety of environmental samples and found the
presence of NTM in 100% of 5 dirt samples, 100% of ditch mud samples,
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77% of 22 house dust samples, and one of two river water samples.134
Water as a source of environmental NTM is well described in a
variety of studies collected from several different water sources. An
analysis of brook water collected from sources in rural Finland found that
NTM was present in 100% of 53 samples.135 In an Australian study, the
presence of MAC was identified by PCR in two water distribution
pipelines. Later sampling during the summer months noted that the
concentration of the organism significantly increased, which implies the
organism multiplied while in the pipeline and became more infectious.136
In a study evaluating patients with MAC, NTM was identified in the home
water samples from 10 patients.137
In a 2013 doctoral dissertation, the relationship between NTM
isolated from a municipal water source and human infection was
evaluated. In this study, water samples were taken from the municipal
water supply in Queensland, Australia and compared with clinical samples
collected from the same area. NTM was isolated in more than 40% of
water samples during summer months and 82% of samples collected
during winter months. The NTM species discovered included both species
that are considered pathogenic to humans as well as nonpathogenic NTM.
M. abscessus was not identified in water samples collected in this study.
It is important to note that this particular NTM species is rarely isolated in
water, as opposed to M. kansassi, which is so strongly associated with
water, it has been termed the “tap water bacillus.” Further investigation
37

was conducted in the homes of 20 patients with a diagnosis of NTM in
which samples collected from showerheads were compared. A total of 7
(35%) patients were diagnosed with the same species of NTM that was
identified in the showerheads of their home. This study also compared
nosocomial, or hospital acquired, and community associated infections
caused by M. fortuitum to the samples identified in the municipal water
samples through strain analysis. Similarities were founds which implies
contamination within the hospital water supply. Strain similarities were not
found in community associated infections caused by M. fortuitum,
indicating that water was likely not the mode of transmission in these
cases.138 See below for comparison data of NTM species identified in this
study in water samples and clinical isolates.
Table 6: Pathogens Collected from Water and Clinical Samples

Pathogens Identified in Water

Pathogens Collected
from Clinical Isolates

M. gordonae

M. lentiflavum

M. lentiflavum

M. szulgai

M. fortuitum

M. fortuitum

M. simiae

M. kansasii

M. kansasii

M. terrae

M. flavescens

M. abscessus

M. chelonae

M. interjectum

	
  

M. intracellulare

M. mucogenicum

	
  
	
  

M. avium complex

Water from home and public water sources has been evaluated. In
a study of 31 patients from the US and Canada with NTM disease due to
38

MAC, M. abscessus, and M. xenopi, the species identified in the patient
was also isolated in their home in 46% of cases.139 In a Saudi study, NTM
was isolated from the mouthwash of 44 (26.3%) subjects that used tap
water versus 10 (33%) subjects that used sterile water.140 In a review, the
authors emphasized the importance of intentionally designing engineered
water systems based on quantitative microbial risk assessment. This
recommendation came following a discussion of numerous studies
isolating NTM, legionellae and Pseudomonas aeruginosa from public
water sources.141 Also, research has evaluated the possibility of
transmission through aerosolized water. Theoretical sources of
aerosolized NTM include primarily showerheads and hot tubs. A study
examining household water and showerheads of patients with NTM
pulmonary disease identified matched environmental and human strains of
M. abscessus, M. lentiflavum, and M. kansasii in 20 patients142 In a study
evaluating 18 public hot tubs and warm water therapy pools, the presence
of NTM in was found in 13 sites (72%). Proper water care using chlorine
or bromine sanitation significantly lowered the concentration of NTM
identified in this study.143
NTM infection from food sources is another possible mode of
transmission for which few data exist. One recent study suggests that
NTM might be transmitted from freshwater fish and fish products following
the review of 92 tissue samples obtained from ponds, retail fresh, frozen
fish and smoked fish products. In this study, nearly 12% of samples
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evaluated tested positive for pathogenic NTM.144
Although NTM was previously believed to only be transmitted from
environmental sources, emerging data suggests that human-to-human
transmission occurs in patients with cystic fibrosis. A 2011 report in which
168 isolates collected from 31 cystic fibrosis patients with NTM infection
due to M. abscessus was tested using whole genome sequencing and
drug susceptibility testing revealed the frequent transmission of multidrug
resistant NTM between patients.145
Despite these reports, the transmission patterns of NTM are not
well described. Transmission from environmental sources seems to occur
from a myriad of soil and water sources that surrounds communities, and,
in some cases, lives in our homes while emerging data indicate that NTM
may even be transmitted from food sources. The factors influencing the
transmission of disease from environmental pathogens remain
unknown.146 Further, the transmission of NTM disease from animals to
human, humans to animals and humans to humans is a critical area of
future research. Improving the understanding of transmission pathways is
critical to crafting a more effective response to this emerging public health
problem.
Diagnosis
The diagnosis of NTM infection involves the correlation of clinical
signs and symptoms with radiological and microbiological findings. Given
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its similar appearance to TB, NTM diagnostics can be especially
challenging as the two diseases may appear identical in disease
presentation. Also like TB, the diagnostic process consists of several
important components and multiple layers.
The microbiological studies process begins with a smear stain,
which determines whether the specimen is a mycobacterium species.
Common smear staining techniques include fluorescence microscopy and
Ziehl-Neelsen. Given the differing sensitivity and specificity of these
staining procedures for various mycobacterium species, a combination of
smear techniques may be used.147 Once the specimens are determined
to be acid fast bacilli, specimens are prepared for isolation. The first step
in this process involves the use of N-acetyl-L-cysteine-sodium hydroxide
(NALC/NaOH), which serves as a decontaminant that prevents the growth
of other bacteria.148
When smears are followed by cultures, the positive identification of
NTM depends of the growth rate of the organism. Most NTM strains grow
within two to three weeks with the exception of rapidly growing
mycobacteria species M. abscessus, M. fortuitum, M. chelonae, and M.
massiliense, which may grow within 7 days.149
Recently developed methods may also be used for a quicker result.
High-performance liquid chromatography (HPLC) is a molecular method
that involves the use of species specific probes.150 HPLC recognizes
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mycobacteria according to variations in mycolic acids, the long-chain fatty
acids resided in the cell wall of mycobacteria.151 The major advantage of
HPLC is rapid species identification.152 However, molecular DNA probes
are available for identifying a select few NTM species including MAC, M.
gordonae, and M. kansasii. Therefore, NTM infection due to other causes
is not diagnosable using this method. The HPLC method is also more
costly, requires reliable laboratory infrastructure and well trained
technicians to carry out the test, which may limit its availability in some
care settings.153,154 PCR restriction fragment length polymorphism
analysis is another molecular technique for identifying mycobacteria on
account of differences in restriction fragments of the 65 kD heat-shock
protein. Sequence analysis of the rpoB gene and 16S ribosomal RNA has
been expanded recently as another method for speciation of NTM.155,156
Significant improvements in the laboratory methods that identify the
presence of mycobacteria have occurred over the last two decades. Also,
species identification has allowed the opportunity to further expand the
clinical and epidemiologic database regarding NTM.157 Despite recent
advances, diagnostics remains challenging for several reasons. First, due
to the ubiquitous presence of NTM species in the environment, the
likelihood of contamination is high and can occur before, during or after
clinical samples are collected. Many possible scenarios exist for
contamination. For example, sputum samples may be contaminated when
traveling through the mouth during collection.158 Following arrival to the
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laboratory, samples may be contaminated by equipment. The
contamination of a fibrotic bronchoscope suction channel has been
reported as the cause of several positive cultures for M. chelonae.159
Given that many mycobacterium species live in water, it has been
reported that liquids used during the culture process exist as another
possible source of contamination.160 For these reasons, the reliance on
microbiological findings must be carefully considered alongside clinical
and radiological. 161,162
The diagnosis of NTM disease is defined by the positive
identification of a pathogenic NTM species in a clinical isolate in addition
to clinical signs and symptoms of disease. In a statement published by
the American Thoracic Society/ Infectious Diseases Society of America
(ATS/IDSA) is the official definition of pulmonary NTM as outlined in the
table below.164
Table 7: ATS/IDSA Official Definition of pulmonary NTM

ATS/IDSA Criteria for pulmonary NTM
1

Chest radiograph showing opacities, nodular or cavitary, or a highresolution computed tomography (HRCT) scan that shows multifocal
bronchiectasis with multiple small nodules; and

2

Three or more sputum specimens positive for acid-fast bacilli (AFB);
and

3

The exclusion of other causes including TB.
The panel of experts emphasized that these criteria were designed
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for the unique infectious processes of MAC, M. kansasii, and M.
abscessus, noting that ATS/IDSA criteria cannot be applied to other
species of NTM because there is not enough data to confirm a similar
infectious process for all species of NTM. 165
Following the diagnosis of NTM infection and the identification of
NTM species, the next critical step in NTM infection management is DST.
For NTM, laboratory isolates are tested against common antimicrobial
agents in order to optimize therapy. This is particularly important because
most NTM strains are usually resistant to agents used to treat TB, leaving
fewer options for treatment as compared to many other diseases. Also,
many preferred agents such as clarithromycin may not be effective in
some strains.167 Current ATS/IDSA guidelines recommend drug
susceptibility tests for MAC against macrolide antibiotic class, M. kansasii
against rifampin, and rapid growing mycobacteria against various
antibiotic classes including newer macrolides and quinolones, doxycycline
and minocycline, and sulfonamides.168
Treatment
The treatment of NTM is long-term and complex consisting of
bacteriologic surveillance, monitoring for drug toxicity, and managing
comorbidities. Also, with the absence of randomized clinical trials
published in peer-reviewed literature, current guidelines for treatment are
based largely on expert opinion using what little data are available.
Guidelines vary depending on site of infection, host characteristics, and
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NTM species. Therapy duration is also highly variable, dependent largely
on repetitive negative cultures for a period of time, usually one year.
Given these long treatment courses, monitoring and managing the
sometimes harmful side effects associated with long-term antibiotic use is
an important component of NTM management. Further, because NTM
patients tend to have underlying diseases coupled with advanced age,
treatment can be complicated with providers having to manage drug
therapy and side effects alongside comorbid conditions and associated
therapy. Finally, all of this requires strong patient compliance over a long
treatment course.
An example of NTM therapy as recommended by the ATS/IDSA for
NTM species MAC for patients who are not HIV positive with pulmonary
infection may include clarithromycin (1000 mg three times per week) or
azithromycin (500 mg three times per week); and rifampin (600 mg three
times per week) or rifabutin (300 mg three times per week); and
ethambutol (25 mg/kg three times per week). For patients with
fibrocavitary MAC lung disease or severe nodular or bronchiectatic
disease, the ATS/IDSA guidelines recommend clarithromycin (500 to 1000
mg daily) or azithromycin (250 mg daily); and rifampin (600 mg daily) or
rifabutin (150 to 300 mg daily); and ethambutol (15 mg/kg daily). In some
cases, streptomycin or amikacin (both 10 to 15 mg/kg three times per
week) may be added as a fourth agent for the first eight weeks. A lower
dose (6 to 8 mg/kg two to three times weekly) may be appropriate for
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patients who are older than 50 years of age, whose weight is <50 kg, or
who require parenteral therapy for longer than two to three months. For
the same patient population with M. kansasii, the second most common
NTM organism, ATS guidelines recommend combination therapy
consisting of isoniazid (300 mg daily), rifampin (600 mg daily), ethambutol
(15 mg/kg per day) in the same patient population. Therapy duration is
generally one year following the first negative culture result assuming
subsequent results are also negative.169
The presence of comorbid conditions also contributes to potential
treatment complications for NTM disease. As many older Americans
maintain regimens of maintenance medications, prolonged concurrent
therapy can present clinicians with many treatment challenges. For this
reason, NTM treatment must be chosen carefully in order to avoid drugdrug interactions with existing and necessary concurrent medication.
Antibiotic classes commonly used to treat NTM cause interaction with
drugs that interact with cytochrome P-450 (CYP), which includes drugs
commonly used to treat a myriad of disorders including anxiety, psychiatric
disorders, seizure disorders, hyperlipidemia, hypertriglyceridemia, atrial
fibrillation, and bleeding disorders.170 In other patient populations such as
patients that are HIV positive, patients with extra pulmonary infection sites
or disseminated disease, or patients with documented resistance following
DST or previous treatment failures, other recommendations using less
proven treatment regimens may be used.
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In select cases of NTM infection, surgical resection may be a
consideration. Indications for surgery have not been uniformly defined,
but are most commonly associated with medication intolerance, drug
resistance, localized cavitation, recurrent or massive hemoptysis, and the
presence of a destroyed lung. The safety of lung resection for NTM lung
disease, particularly thoracoscopic right middle lobe lobectomy and
lingulectomy, has been reported as favorable in carefully selected patient
populations and under the care of experienced surgeons. Data have
shown that surgery provides improved microbiologic response for
refractory organisms such as M. abscessus as compared to medication
regimens alone.171,172,173
Epidemiology
Infections caused by NTM are an increasingly important cause of
morbidity and mortality. Infection is the result of the interaction between
exposure load and host characteristics including underlying diseases, age,
behaviors, and genetic predispositions. Virtually everyone is routinely
exposed to NTM, although most do not develop clinical signs of infection.
The factors predisposing one to infection are not well understood.174
United States population-based data indicate that the number of deaths
from NTM disease is growing. During the years 1999 through 2010, NTM
disease was reported as an immediate cause of death in 2,990 people in
the United States with a combined overall mean age-adjusted mortality
rate of 0.1 per 100,000 person/years. Persons aged 55 years and older,
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women, those living in Hawaii and Louisiana, and those of non-Hispanic,
white ethnicity had higher mortality rates. In fact, some evidence suggests
that NTM is a more common cause of death in the US than TB.175 The
majority of NTM deaths were reported in the hospital setting.176
Additionally, there is a strong association between age and NTM mortality,
which was found to be significantly higher in patients older than 65 years.
In addition to the presence of comorbidities common in this population,
advanced age itself was determined to be a strong predictor of
mortality.177,178 Morbidity can also be significant for patients with NTM
infection. A national cohort study found that respiratory failure is more
common in patients with NTM after adjusting for potential confounders
such as age and the presence of comorbidities.179
The epidemiology of NTM is vastly different from TB, and has
changed significantly in recent years. First, NTM is becoming increasingly
common in wealthy industrialized countries, while respective TB rates are
on the decline.180 However, NTM is a non-reportable disease in the US
and its epidemiology is not well described in the literature or by other
sources of disease surveillance, resulting in infection rates being difficult
to piece together. The prevalence of disease in North America was
reported at 1.6-1.8 per 100,000 in the 1980s whereas recent reports
record a prevalence of 14.1 per 100,000.181 Current reports indicate that
NTM exceeds TB infection rates in the USA according to data from
Oregon found the total age-adjusted prevalence of NTM was reported at
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8.6 per 100,000 cases in the 2005-2006. This number increased to 20.4
per 100,000 in adults 50 years of age and older. The median age was 66
years and 59% were females.182 In a combined report of four other
regions in 2010, the mean annual prevalence was 5.5 per 100,000,
ranging from 1.7 per 100,000 in Southern Colorado to 6.7 per 100,000 in
Southern California.183 According to findings from a national Medicare
claims data study, the annual prevalence of NTM in the population older
than 65 years old significantly increased from 20 cases per 100,000
persons in 1997 to 47 cases per 100,000 persons in 2007. The study also
found interesting demographic features, including that Caucasians
accounted for 90% of cases followed by Asians/Pacific Islanders and
African-Americans.184,185
A number of explanations exist for these trends. First, North
America and Europe demonstrate a dramatic decline in TB rates given
successful public health interventions coupled with the development of
anti-TB medication over the last century. Also, the recognition of NTM
along with the ongoing identification of more NTM species have allowed
clinicians to improve diagnostic methods so that NTM cases are not
misdiagnosed and treated as TB. Some of this technology is not available
or affordable in developing countries, resulting in NTM not only being
misdiagnosed and treated, but also facilitating resistance to anti-TB drugs
characterizing MDR and XDR-TB. Another important contributor to the
rise in NTM infection in North America and Europe is a population aging.
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Environmental factors are also important as warm and humid climates
have been associated with higher rates of infection.
The population composition of North America and many parts of
Europe demonstrate population aging coupled with overall population
shrinking. In the US, population composition is uniquely impacted by the
baby boomer generational cohort. The baby boom is characterized by the
post World War II bump in birth rates that began in the middle of 1946 and
continued into 1960. This noticeable increase in births exists alongside a
decline in births during subsequent years, resulting in the baby boomers
commanding a significant proportion of the population. In 2010, the
elderly in the US was estimated to be approximately 40.2 million. Given
that baby boomers are just now entering retirement, the number of elderly
Americans is expected to grow in coming decades. Further, population
composition projections demonstrate this trend will remain as the baby
boomer cohort enters the very elderly years.186 Projections from the US
Census Bureau show population structure challenges associated with the
baby boomer generational cohort marks only the beginning of elderly
Americans making up a significant proportion of the population.187 As the
generation after the baby boomers enters retirement years, the number of
elderly Americans is expected to increase to 88.5 million by 2050.188 See
the figures below for projections from the US Census Bureau that
demonstrate the impact of the baby boomer generational cohort relative to
other generations beginning in 2012, 2035 and 2060.189
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Figure 4: US population by age and sex in 2012 and projections
Given that many entitlement programs in the developed world are
in place relying on the support of younger citizens, population aging and
shrinking has resulted in deficits and shortfalls. In the US, the future of
Medicare and social security have been an important political debate for
several election cycles as policy makers have expressed concern with
funding these programs in the future using conventional methods. Also,
the high utilization of healthcare resources by the aging population has
also been an important cost driver for healthcare in the US that is only
expected to worsen as the baby boomers continue to age. Therefore,
population aging has had many important implications for the funding of
public programs as well as managing the cost of many illnesses
associated with the elderly including NTM in the US and in other
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developed countries.191,192
NTM prevalence differs by geographic region due to specific
environmental factors linked to climate, water, and soil exposure. Given
the most common sources of NTM species are water and soil, swampy,
humid southeastern states in the US have more cases of disease than the
dry west or the cold north. A report of pulmonary NTM identified 55
counties in 8 states with a particularly high risk of infection, which included
parts of California, New York, Florida, Hawaii, Louisiana, Oklahoma,
Wisconsin, and Pennsylvania. A map of state reported variations in NTM
infection are illustrated blow.193

Figure 5: NTM rates by state in the US
NTM is an important infectious disease that represents a new
public health challenge. Given its similarity to TB both in both
presentation and microbiology, NTM was only recently recognized as a
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human pathogen.194,195 Diseases caused by NTM generally have
prolonged treatment in order to achieve a complete cure. Therefore the
prevalence is far greater than the incidence. While efforts in treatment
and surveillance of TB have resulted in a decrease in the incidence in
recent years, the incidence of NTM is increasing which has classified NTM
as an emerging public health problem in the US and the world. 196,197,198 In
a national cohort study, populations underwent screening for the NTM
species M. intracellulare during the years 1971–1972 and 1999–2000. In
the earlier cohort, a total of 1,490 participants were evaluated and 7,384
were included in the later cohort. This study found that one in nine
participants in the 1970s tested positive as compared to one in six in 1999
and 2000. The authors conclude these findings are consistent with the
overall rising rates of NTM in the US.199 According to a study conducted
in Oregon, NTM rates were in excess of TB in the population sampled.
Given that Oregon has TB rates comparable to fourteen other states as
well as demographic similarities with thirty-five other states, the authors
suggest that NTM is likely more prevalent than TB in several states in the
US.200
Recent surveillance data was presented at the 2016 IDSA meeting
in New Orleans, LA. In this study, data was retrieved from the National
Center for Health Statistics between the years 1999 and 2014 for cases in
which NTM was noted as a contributing or underlying cause of death.
This database includes causes of death as recorded on death certificates
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along with demographic data of the deceased from all fifty states in the
US. Demographic data was collected including age, race, gender and
comorbid conditions. This study established the mortality burden of NTM
at 2.3 per 1,000,000 persons over the past 15 years. This study also
confirmed established demographic features of the disease, noting that
mortality was significantly higher among older white women. Also,
comorbid conditions most strongly associated with mortality were
structural lung diseases such as cystic fibrosis, bronchiectasis and
pneumoconiosis. Further, this study found that HIV status was the only
non-pulmonary comorbidity that was found to be a predictor of mortality;
however, data from this study noted that HIV co-infection rates in patients
dying with NTM infection declined during the fifteen year study period as
NTM rates in patients without HIV infection has increased. The purpose of
this study was to provide national surveillance data for NTM mortality rates
given that this disease is not reportable and the burden of mortality is
unknown.201
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CHAPTER 2: STATEMENT OF THE PROBLEM
AND LITERATURE REVIEW
Mycobacterial infections are a source of significant economic
burden in the US and the world. The cost burden of TB and NTM are
multifaceted, including complex direct medical costs which include not
only managing the infection and related therapies and procedures, but
also minimizing the impact of common side effects, identifying and
preventing potentially dangerous adverse reactions, managing comorbid
conditions as they relate to therapy, and minimizing the cost of treatment
failures and other therapy challenges. Given that health care costs have
been key factors in national economies worldwide, controlling health care
costs has become a priority for essentially all countries in the world, and is
an important area of research.
Mycobacterium tuberculosis
Mycobacterium tuberculosis (TB) represents a worldwide public
health challenge with corresponding cost implications. In the developed
world, TB was once a nearly eradicated disease that has resurfaced
secondary a number of factors. Among these are immune suppression as
a result to the HIV/AIDS epidemic, diabetes mellitus, or immune
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suppression therapies, immigration, and the development of drug
resistance.202 In the underdeveloped world, TB has emerged with an
often disproportionately high rate of HIV/AIDS, malnutrition and other
poverty related causes of immune suppression, coupled with resource
constrained health care delivery systems. In many of these countries,
national TB programs have been established to deliver TB related
treatment at no direct cost to the patient. However, the reality of many TB
programs in resource-constrained countries is characterized by a failure of
to meet public demand, limited access to drug therapies, and a reliance on
outdated or incomplete laboratory methods. Also, indirect costs
associated with TB disease such as food and travel can result in further
impoverishment for the very poor. This situation is often exacerbated by
the loss of wages secondary to the disease process and the time
investment necessary to seek treatment. In these cases, adding the cost
of direct medical care can be potentially devastating to many vulnerable
populations.203
TB in the Underdeveloped World
The prevalence of TB is disproportionately high in developing
countries located primarily in Asia and Africa. Given the strong
association between TB and poverty, the risk of driving vulnerable
populations into further poverty as a result of TB infection is important with
significant implications for long-term quality of life. Several studies have
examined cost as a means of measuring the impact of TB on individuals
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and their families as well as in the context of national resource planning.
In the current body of medical literature, the financial burden of TB has
been measured from a variety of perspectives. Also, cost data are widely
available in the context of national and international policy, resource
planning, technology assessment as well as the measurement direct and
indirect treatment cost relevant to patients and their families. The
conclusion of the majority of these studies is not encouraging, noting that
TB can be particularly devastating for patients, their families and/or
caregivers, as well as threatens the fragile healthcare delivery systems in
resource scarce countries.
Program Delivery Costs
The TB delivery system in most countries is complex resulting in
many challenges in measuring cost. For example, in countries that
theoretically provide TB care at no direct cost to the patient, free services
may not be available due to resource constraints, may not be offered to
patients due to unavailability or corruption, or indirect expenses or lost
wages may not be offset with vouchers or other expense reimbursement
and wage replacement programs. Only one of these factors being present
within many populations can be financially devastating.
The financial impact of TB disease is heterogeneous in the
developing world and dependent upon many important factors. A
systematic review of 49 studies from a variety of low resource countries
located in Africa, Asia, and Latin America found large variations in costs
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often within the same care setting and among different care settings, but
most of which were significant relative to middle and low income
populations. Despite TB related treatment having been delivered at no
direct cost to the patient in some care settings included in this analysis,
this study found that patients were sometimes not offered free services
despite their availability, patients received services from private sector
providers that were not included in national TB programs, or patients were
responsible for ancillary medical costs such as adjunct therapy for TB
drugs or routine hospitalization. In addition to direct medical costs, this
systematic review also found significant indirect costs, which included
transportation to treatment facilities and food costs during travel. This
study emphasized that travel and food vouchers could be an important
part of a successful TB program for low-income populations. Perhaps the
most critical factor driving cost identified across studies was the ability to
work and earn wages. Both treatment obligations and the physical impact
of illness undermined the ability to work and earn normal wages placed
patients at the highest risk of financial vulnerability. The average cost
breakdown across studies was as follows: 20% direct medical care, 20%
indirect medical care, and 60% lost wages.204
Perhaps one of the least described variables is the impact of illness
on the ability to earn wages. As the previous study notes, lost wages are
one of the most important cost factors related to the impact on the patient.
Lost wages are driven by several inputs: time away from work seeking
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treatment including hospitalization, the impact of the disease process on
the ability to work, and the impact of wage earning on family members and
caregivers. Despite this, lost wages in low to middle resource countries is
rarely and often incompletely measured. Based on the results from a
systematic review, it is believed that lost wages accounts for as much as
60% of total cost experienced by patients and their families.205 For this
reason, the economic impact of TB was noted as a major concern
following an interview of TB patients at an urban clinic in Bombay, India.
This study sought to understand the perceptions of TB and the impact of a
TB diagnosis and subsequent treatment on the daily lives of patients.
Following intense interviews of 16 respondents, men expressed financial
concerns including: loss of wages, reduced capacity for work, poor job
performance, and absenteeism from work. It is important to note that the
surveyed men were primarily self-employed so they did not express
concerns about losing their job, but women were more likely to be
employed in this sample and did express that concern. Women also
feared rejection by their husbands while single women feared that their
illness may reduce their chances of finding a husband, which also has
important financial implications.206 Another focus group based study
conducted in rural India of 304 TB patients found that an average of 83
work days were lost following a diagnosis of TB.207 Additionally, the
disease process itself has a significant physical toll, which has important
implications for one’s ability to work while infected with TB. In fact, body
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composition changes, or wasting, is one of the most notable features of
active disease and is attributable to a number of factors which may include
a loss of appetite as well as metabolic changes secondary to inflammatory
and immune responses.208,209,210,211 The relationship between wasting and
physical impairment is well described, although the economic implications
of this relationship are not that well understood.212,213 However, it is
noteworthy that emerging research has identified important risk factors for
wasting including low socio-economic status and risk behaviors
associated with low socio-economic status, indicating the impact of
disease is more pronounced in vulnerable populations.214 Wasting is also
an important risk factor for mortality, which also has important economic
implications.215 A study indicated that over 500,000 disability-adjusted life
years are lost due to illness and mortality secondary to TB each year in
the Philippines, with an economic cost equivalent to $145 million.216
Several inquiries into the national TB program in China illustrate
many of the realities of TB care as found in developing countries. China
provides TB related treatment to patients free of charge as the result of a
national program developed and subsidized by the World Bank following a
resurgence in TB rates in the 1990s. This national program consists of a
local delivery system on the county level and provides 6 months of TB
therapy for treatment naïve patients and 8 months for treatment
experienced patients along with a sputum smear test, and chest x-ray at a
local treatment center. Initial reports evaluating the national TB program
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in China, early in its implementation phase, boasted positive results,
reporting 98.4% adherence in a population of over 55,000 patients.217
However, subsequent reports have noted that TB treatment providers
recommend treatment courses beyond what is provided by the national TB
program, along with additional laboratory methods, imaging studies and
ancillary treatment such as liver preserving therapies at an additional cost
to patients.218 A systematic review measuring direct medical costs
incurred by TB patients in China sought to trace the relationship between
cost and adherence and completion of TB related treatment. Data
extrapolated from published studies and data from Chinese and
international organizations found that low-income patients pay within an
average range of 42% to 119% of their annual household income for TB
treatment in direct medical care costs. Also, 73% of TB patients admitted
to having interrupted or suspended their treatment, citing cost as the most
common reason. This study found that despite the Chinese policy of TB
care delivered at no cost to patients, TB patients and their families are
paying significantly and often failing to complete their treatment as a result
of direct medical cost.219
Another systematic review focusing on countries in sub-Saharan
Africa pulled direct and indirect cost data published in thirty studies from
the following countries: Zambia, Nigeria, Kenya, Malawi, Ethiopia,
Uganda, South Africa, Sierra Leone, Gambia, Botswana and Tanzania.
This review included a descriptive classification of costs including those
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incurred in the private sector prior to patients being transferred to the
public sector for treatment through free national TB programs. In addition
to private sector provider fees, additional direct costs included health
insurance premiums, prepayment fees, and tipping of medical providers
as practiced in Uganda. Diagnostic, treatment and hospitalization costs
were reported and sometimes included admission fees, culture and
imaging costs, treatment costs, and needle and syringe costs. Another
descriptive cost item noted in five studies were costs associated with visits
to traditional healers, and four studies noted the cost of food including
special therapeutic food. Of course, travel costs were also noted as well
as time costs, which equated to lost work time. Not all studies reported
every cost category, but in many cases the presence of only one of these
costs could easily exceed the resources of the poor and some middleincome patients. For example, the cost of TB care reported in Malawi
relative to monthly income ranged from 129% to 244% in the sample
evaluated. More than one cost classification was present for TB patients
in Zambia with 16% of monthly income spent on transportation costs, 66%
spent on food costs, and a range of 10% to 132% having been allocated
to treatment costs. In Zambia, female patients were reported to spend
much more on TB treatment than male patients. In Ethiopia, 48% of
monthly income was spent on treatment and 35% was spent on
pretreatment. In addition to patient cost, eight studies noted direct and
indirect costs incurred by caregivers or guardians. In twenty of the thirty
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studies, direct and indirect costs associated with TB were found to be
catastrophic for those of average income while twenty five studies found
costs to be catastrophic for those of low income as defined as the bottom
20%. Therefore, a diagnosis of TB in sub-Saharan Africa can either cause
or exacerbate poverty as well as impact the willingness for patients to
seek care for TB. The delay of treatment has additional implications,
which can result in the presentation of more advanced disease and
facilitate the transmission of disease to others.220
Following a survey based study of national TB programs in Ghana,
Vietnam and the Dominican Republic, direct and indirect costs incurred by
patients were measured from a sample of TB patients who had undergone
at least one month of therapy. This study found the economic impact of
TB to be significant in care settings on three different continents. For
example, between 27% and 70% of patients reported that they had
stopped working as a result of their diagnosis. Also, between 5% and
37% sold property and between 17% and 47% borrowed money in order
to pay for direct and indirect medical costs and account for lost wages.
The total average costs incurred by patients in all care settings were
equivalent to approximately 1 year of individual income.221
The impact of TB-related expenses on accessing and adhering to
quality care has been addressed in several reports by the World Health
Organization (WHO). In its report encouraging all states to adopt some
form of universal access to healthcare resources, TB is noted as one
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particularly devastating disease that can result in financial hardship if care
is accessed without financial support.222 Also, a subsequent report noting
the potentially catastrophic financial costs TB affected patients and their
families face in many care settings due to direct and indirect health care
costs also emphasized the need for income replacement and social
support in the event of illness.223
Given the consistent findings from individual studies and systematic
reviews, the weaknesses of many national TB programs that fail to deliver
quality and cost effective TB care has been widely documented. As a
result, several studies have been published to facilitate improvements in
the allocation of TB diagnostic and treatment resources.
A study of the national TB program in South Africa found
insufficient resources being allocating in research and development
despite South Africa having had the second largest incidence rate of TB in
the world according to 2010 data. The epidemic in South Africa has been
facilitated by the HIV/AIDS epidemic, which has disproportionately
affected sub-Sahara African nations. According to the WHO, TB is the
most common co-infection disease of HIV/AIDS and is the cause of death
of one quarter of HIV/AIDS patients.224 Reports from sub-Saharan Africa
reveal that TB is often undiagnosed in HIV/AIDS patients and death due to
disseminated disease is not uncommon.225,226 South African TB
prevention policy encourages the 1.5 million HIV/AIDS patients to receive
first line drug isoniazid as part of active TB disease prevention therapy.
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When this figure is combined with the nearly half million cases of active
TB annually, this equates to nearly 2 million treatment regimens. This
study likewise found that South Africa is providing only a fraction of
treatment demand due to resource constraints.227
Research and new drug development for new treatment regimens
have been slow. The model has historically been to rely on higher
resource countries to facilitate new drug discovery, but this model has not
been effective for TB for several reasons. First, the global impact of TB
has been outside of high resource countries resulting in the discovery of
new drugs having a low impact on the settings and funding for new
therapies. Also, high prevalence TB countries tend to be low to middle
resource with public delivery systems in place resulting in a resourceconstrained public sector unable to pay market premiums for new
therapies. For these reasons, TB research and development will not
provide a suitable return on investment as would be expected by the
private sector in high resource countries. Despite arguments that drug
development should still occur due to a moral obligation, new drug
development for TB has remained inadequate relative to global demand.
As a result, policy makers are beginning to encourage a stronger
investment in research and development in countries with a high burden of
disease, offering a mathematical model demonstrating a suitable return on
investment given the crippling disease burden in some countries.228 The
table below provides a summary of costs of TB delivery systems.
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Table 8: Program delivery costs for budgets and patients
Author(s)
Tanimura
et al.

Setting
Africa, Asia,
and Latin
America
Bombay,
India

Study Type
Systematic
Review of
literature
Interview

Rajeswari
et al.
Praygod
et al.

Rural India

Survey

Tanzania

Crosssectional of
newly
diagnosed
TB patients
2007-2008

Peabody
et al.

Philippines

Surveys
and national
datasets

Long et al.

China

Systematic
Review of
literature

Barter et
al.

SubSaharan
Africa

Systematic
Review of
literature

30 studies

Mauch et
al.

Ghana,
Vietnam,
and
Dominican
Republic

Survey

135
patients
with TB

Nair et al.
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Study Size
49 studies

Findings
20% Direct, 20%
Indirect, 60% Lost
Wages
16 low
44% Male, majority
income
were self employed and
patients
reported lost earning;
with TB
66% Female, reported
job loss as most were
employed and rejection
by husband or potential
mate
304
83 average work days
respondents lost
201
Female: 37.8% (76)
pulmonary
Male: 62.2% (124)
TB patients
HIV +: 51.7% (104)
Wasting strongly
associated with risk
behaviors in vulnerable
low socio-economic
populations
Population
Wasting associated
based data with $145 million in
costs and 500,000
disability adjusted life
years
247 studies, Direct medical care
4 national
42%-119% of annual
survey
income, 73% did not
datasets
finish treatment due to
cost

Cost of treatment
was catastrophic for
average income in 20
studies; bottom 20%
income in 25 studies
27%-70% stopped
working, 5%-37%
sold property, 17%47% borrowed
money, average cost
was equivalent to 1
year of individual
income

Technology Costs
The success of cost effective national TB programs depends on the
availability of accurate and affordable diagnostic and treatment
technology. Researchers and policymakers agree that current diagnostic
technology is inadequate to address global demand. Given that one third
of the world is believed to have undiagnosed disease, under diagnosis
remains an important challenge to global TB control. The epidemiology of
TB and its association with the poor in both high and low resource
countries also has financial implications for diagnostic technology.
Therefore, the design of effective TB screening programs along with the
use of cost effective diagnostic methods remains a common discussion
the peer-reviewed published literature. The appropriate use of resources
has also been the primary endpoint for several studies examining current
diagnostic methods.
The New Diagnostics Working Group of the Stop TB partnership
published a report that summarizes the current state of TB testing
technology while summarizing the challenges in new technology
development. The report also included a wish list outlining the
characteristics of the ideal testing methodology.229 A WHO report
addressed the unmet needs of TB diagnostics offering a more detailed
wish list for TB diagnostic test characteristics. The WHO also described
the need for the availability of different tests relative to care setting and
populations.230
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In a review specifically evaluating diagnostic technology available
to low resource countries with a higher proportion of TB, Molicotti and
colleagues discuss the cost implications of diagnostic methods relative to
effectively diagnosing disease. Modeling studies have shown 400,000
lives could be saved annually with the adoption of rapid TB testing
techniques with a sensitivity greater than 85% for both smear-positive and
smear-negative cases along with a specificity of 97%.231 Given current
technology and cost, the WHO recommends liquid culture systems in low
resource settings. However, the purchase and maintenance of laboratory
instruments along the laboratory infrastructure to conduct liquid culture
testing simply does not exist in many low resource countries.232 Instead,
many low resource countries continue to rely on the microscopic
examination using the Ziehl-Neelsen smear method given its low cost of
approximately $0.50 for two sputum smear studies. However, poorly
maintained laboratory equipment, understaffing, and the lack of
consistently available clean water and electricity severely compromise this
the sensitivity of this test. The Ziehl-Neelsen has been proven especially
insensitive in populations with a compromised immune system and in
pediatrics.233 Further, an important limitation of smear testing alone is that
this laboratory method does not distinguish TB from other mycobacterium
species or determine drug susceptibility, which contributes to
inappropriate antibiotic use and the escalation of healthcare costs in these
care settings.
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Although many studies acknowledge the importance of cost
effective diagnostics, especially for low and middle resource countries, few
studies are available that standardize and measure the of cost diagnostic
technology. One cost study evaluated the affordability of new tests in 36
high burden countries. New diagnostic test types were categorized into
four groups: rapid-sputum, non-sputum biomarker, triage test followed by
confirmatory testing, and drug susceptibility testing. The costs of these
tests were estimated based on the unit cost multiplied by the number of
tests and compared with the current spending on conventional
diagnostics. The conclusions of this study found that non-sputum
biomarker testing and triage testing followed by confirmatory testing are
affordable with current resources. The use of rapid-sputum tests and drug
susceptibility testing would only be possible with additional funding. It is
important to note that this study only considered variable testing cost,
ignoring fixed costs such as equipment and facilities.234 In developed
countries where the investment in additional infrastructure and equipment
costs may not be necessary, the examination of variable cost alone might
provide a complete enough picture. For low resource countries, especially
where infrastructure is lacking and equipment may be unsuitable, fixed
costs represent a critical part of the equation. Another challenge in
estimating cost lies in the high variability of both unit and secondary
material cost. For example, smear cost data vary between $0.26 and
$10.5 and culture cost ranges from $1.63 to $62.01. The cost range for a
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combination unit consisting of both smear and culture ranges from $2.27
to $48.23.235
In order to accurately represent cost, some studies have sought to
measure the economic impact of TB. Economic costs include a variety of
characteristics beyond the variable costs associated with a laboratory test,
but also include the investment of additional resources in order to be able
to conduct the test properly. These costs may be offset by the economic
impact of the test by diagnosing TB in populations earlier or detecting the
disease in populations in which the disease may be undiagnosed. In
these cases, economic cost would be heavily impacted by the initiation of
therapy earlier, the reduction of transmission, fewer wages lost, and fewer
complications of treatment. Sohn and researchers evaluated several cost
studies in a review noting the difference in financial versus economic costs
in TB diagnostic testing. According to this assessment, the cost of
diagnostic testing extends well “beyond the simple boundaries of current
consumable costs and simple comparisons of equipment cost.” Instead,
the need to measure economic cost as a complete assessment of cost is
necessary to establish evidence-based guidelines.236
Drug Resistance Cost
The cost of TB treatment is exacerbated following a diagnosis of
multi-drug resistant TB (MDR-TB) or extreme drug-resistant (XDR-TB).
MDR-TB is defined by drug resistance to specific first line therapies
isoniazid and rifampin. XDR-TB is likewise resistant to first line therapies
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in addition to any fluoroquinolone and one of the following three injectable
second-line drugs: amikacin, kanamycin, and capreomycin.237,238,239 In
2010, an estimated .4% of TB cases were drug resistant worldwide, which
equates to 440,000 cases annually.240 This number is expected to
increase as inadequate treatment coupled with the transmission of drug
resistant strains of disease are expected to continue. Official numbers,
however, remain unreported. According to the WHO, less than 30,000
cases of M/XDR-TB were reported in 2008, which is believed to represent
only 7% of new cases that same year. Also, WHO guidelines for the
management of M/XDR-TB were unmet in 60% of reported cases.241
Treatment costs for X/MDR-TB alone range from 9 to 25 times the cost of
treating drug susceptible TB, and treatment courses can be up to 3 times
standard duration.242,243
The financial impact of MDR-TB disease on the patient and his or
her family is not well described. A 2010 study interview-based in Ecuador
documented total out of pocket treatment costs reported by patients
following 2 months of therapy, noting the average for drug susceptible
patients with TB at $960 as compared to $6880 for patients with MDR-TB.
Of the 118 patients interviewed for this study, only 14 patients were
infected with MDR-TB.244 In national budgets, the relatively low incidence
of MDR-TB and XDR-TB commands a disproportionately high percentage
of national TB program budgets. In South Africa, for example, MDR-TB
accounted for 2% of TB cases in 2011 while consuming over 30% of the
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total national budget during the same year.245 The continued spread of
MDR-TB and XDR-TB in low-resource countries can be potentially
devastating to governments with high TB prevalence along with increasing
MDR-TB and XDR-TB. In some countries, these direct medical care
expenses are shared between governments and TB patients and their
families, resulting in both bankrupting national governments and
facilitating poverty in vulnerable populations. Also, indirect medical costs
can be even more economically devastating as compared to drug
susceptible TB. The consequences of more severe disease are longer
treatment courses resulting in longer periods of travel, food costs, and lost
wages.
A systematic review evaluating the cost of MDR-TB treatment along
with identifying cost drivers following the assessment of 420 studies
published in five languages found only four studies with quality data that
could be extracted and adjusted to American dollars and international
dollars as well as adjusted for inflation for comparison within a common
year. These four studies contained cost data from care settings in Peru,
the Philippines, Estonia, and Russia, noting that the largest influence on
cost was hospitalization. Many national TB programs use hospital care
settings to ensure patient compliance and prevent disease transmission,
but the authors note that the use of outpatient care settings represent a
better use of resources even with the added expense of food and travel
vouchers. The use of vouchers has been proposed by the WHO to reduce
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the impact of indirect cost on patients and their families but also better
ensure patient compliance to treatment courses.246 The second largest
cost driver across studies was the use of expensive second line drugs,
which is an unavoidable expense for patients with resistant disease. The
authors suggest that despite the cost of expensive therapies, MDR-TB
management delivered in an outpatient setting can still be cost effective in
low and middle resource countries.247 This study also offered important
implications for the availability of cost data specifically for MDR-TB when a
systematic review yielded less than 1% of studies evaluated that included
enough quality data to be included. Clearly, the cost of MDR-TB has not
been adequately measured. A literature review searching for comparable
cost data for XDR-TB revealed no reliable data from any care settings in
the developing world. See the table below for a summary of costs
measured in the literature associated with treating drug resistant TB.
Table 9: MDR-TB in Resource Scarce Care Settings
Setting
Author(s)
Rouzier et Ecuador
al.

Study
Type
Interview

Study Size

Findings

188
respondents

Pooran et
al.

National
datasets

Population
based data

Drug costs: $960
for TB, $6880 for
MDR-TB
MDR-TB 2% of
cases, 30% of
national budget
Estonia: $10,880
Peru: $2,423
Philippines: $3,613
Russia: $14.657
Cost drivers:
hospitalization and
second line drugs

South
Africa

Fitzpatrick Peru,
Systematic
and Floyd Philippines, Review
Estonia,
Russia

73

420 studies

TB in the developed world
The epidemiology of TB in the developed world exists in sharp
contrast to that of the developing world. In local populations, TB rates in
high resource countries are associated with several distinct factors. First,
the use of immune suppression therapies for cancer treatment, posttransplant therapy or immune modulation therapy for auto-immune
diseases have created a risk group that only exists in resource rich
countries where advanced therapy options are widely available. Also,
comorbid conditions that affect the immune system including underlying
pulmonary diseases, diabetes mellitus,248 and advanced HIV/AIDS is a
risk factor for active TB all over the world including the industrialized
west.249 Behavioral factors play an important role such as diet and
malnutrition, alcoholism, and smoking tobacco, particularly in vulnerable
populations.250
In the industrialized west, social determinants of health are strong
predictors of TB infection. In a master’s thesis, the disparity of disease
incidence in local populations was studied in both Canada and New
Zealand. In both countries, a higher incidence of TB has been recorded in
local aboriginal populations in Alberta, Canada as well as the Maoria and
Pacific populations in New Zealand. This study identified key individuals
involved in the transmission of TB within their communities based on
contact tracing and strain analysis, noting that substance use and a delay
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in accessing treatment were common characteristics from both
populations. The author notes that future research in this area might
solidify this association by studying the impact of other characteristics of
vulnerable populations such as poverty and unemployment.251 Despite
the presence of these risk factors in key populations in North America and
Europe, TB rates have remained stable or declined in local populations.
Immigration remains one of the strongest predictors of TB infection
in North America and Europe, particularly those who migrated from high
HIV and TB burden countries. In fact, more than half of active TB cases
are diagnosed in immigrant populations.252,253 In the UK, the incidence of
disease in local populations has fallen 5% between the years 1998 and
2008 and likewise increased by 94% in foreign-born populations during
the same years.254 In the years 2000-2013, TB cases in locally born
populations have actually decreased by half in the US, Canada, and
Europe while rates among immigrant populations have increased. The
European Centre for Disease Prevention and Control and the WHO
Regional Office for Europe released a joint report in 2015 noting that 28%
of TB cases in Europe in 2013 were in foreign-born populations.255 In
Western Europe, a 2010 report estimates this average is excess of
40%.256 In some states, the prevalence of disease in the foreign-born
account for a resounding majority: Luxemburg (94.7%), Sweden (88.7%),
Malta (88.0%), Norway (86.0%), Cyprus (85.4%), Netherlands (73.9%),
Switzerland (75.3%), and United Kingdom (70.1%).257 In the United
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States, the CDC reported that 64.6% of TB patients were born outside the
US in 2013.258 Immigration rates to the US are expected to continue if not
increase in coming years. Each year, approximately 450,000 persons are
admitted to the United States on an immigrant visa, and 50,000–70,000
are admitted as refugees.259
Migrant Populations
Immigration status alone is not a predictor for TB because the
prevalence of disease is much more pronounced in select immigrant
groups than others. Among the immigrant populations at a particularly
high risk are those from moderate to high TB burden countries. Also,
immigrants having arrived within 5 years, termed “new entrants,” are
another important risk group.260 In the UK, new entrants are believed to
account for an estimated 50% of TB cases in the foreign-born
population.261 Finally, immigrant populations with comorbidities represent
important risk groups for developing active disease such as HIV/AIDS.262
According to the European Centre for Disease Prevention and Control and
the WHO Regional Office for Europe, data were available in 36 countries
regarding TB and HIV noting a co-infection rate of 7.8%. The 2012 joint
analysis reported a co-infection rate of 6.1%, which confirms the 18%
increase in co-infection rates annually that has occurred in Europe since
2004. It is important to note that this figure only includes data from 36
reporting countries, and only 219,095 of 324,084 TB patients had a
documented history of HIV testing. Therefore, it is likely that this

76

documented co-infection rate is under-reported.263
The presence of TB in immigrant populations can be explained by
three important pathways. First, immigrants arriving to destination
countries may have been previously exposed and infected with active
disease while residing in their home countries and represent cases of
active disease upon arrival. Also, immigrants may be infected with latent
disease upon arrival, which activates following entry into destination
country. Third, immigrant populations acquire TB from local transmission
following exposure most likely to peers from moderate to high burden
countries.264 Immigration from these countries is expected to remain a
key factor in TB epidemiology as the United Nations note immigration
figures in 2013 alone was 232 million, representing a 50% increase over
the preceding two decades. The 2013 UN report explains migration is
expected to continue to increase secondary to globalization, conflict and
financial and economic reasons.265
The impact of immigration on TB rates is expected to be more
measurable given the recent refugee crisis secondary to current conflicts
in Iraq and Syria. According to Amnesty International, over half of Syria’s
population is currently displaced. While some remain displaced within
Syria, the majority of refugees reside in neighboring countries including
Turkey, Lebanon, Jordan, Iraq and Egypt.266 In 2015, European countries
noted a major influx of Syrian refugees into Europe, coming from both
Syria and refugee centers in neighboring countries. The number of first
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time applicants for asylum in European Union countries more than
doubled from 563,000 in 2014 to almost 1.26 million in 2015. Syrian
refugees represented 29% of the total number of first time applications in
2015, 14% from Afghanistan, and 10% from Iraq.267 The US has pledged
to accept 10,000 Syrian refugees in 2015, increasing allowances in the
three subsequent years for an average of 70,000 to 85,000 annually.268
As of February 2016, Canada has accepted over 25,000 Syrian
refugees.269 These numbers exist in excess of regular and projected total
immigration numbers including asylum seekers, and represent important
implications for immigration, population demographics and resulting public
health policy in many countries. Regular immigration in the US includes
approximately 450,000 persons using immigrant visas and between
50,000 and 70,000 as refugees.270
Many industrialized states have created and executed extremely
successful public health programs that have controlled TB rates as evident
in its decline in local populations. These programs seek to include the
diagnosis of TB in early stages of disease, initiate treatment while
ensuring patient compliance, and trace possible transmission contacts.
However, this approach is only relevant in cases in which TB is acquired
following arrival to destination countries and fails to identify and treat
cases of latent and active disease present in immigrant populations during
the migration process. Policies specifically designed to target migrant
populations represents an emerging need in many countries as part of a
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more comprehensive TB program aimed at reducing the burden of
disease both local and migrant populations.
In the US, programs for screening and managing related treatment
for immigrants diagnosed with TB is managed according to the Directly
Observed Therapy, Short-course (DOTS) national framework.271 DOTS is
an approach to TB surveillance and treatment recommended by the WHO
that requires first an investment from all levels of government internally as
well as international partnership in order to enhance TB monitoring,
surveillance and training. First, DOTS emphasizes the need for smear
microscopy followed by culture and drug susceptibility testing for the
accurate diagnosis of disease as well as the identification of drug resistant
cases. Next, DOTS calls for a standardized treatment regimen of six to
nine months in total duration, the first two months of which should be
directly observed by a healthcare worker or community health worker.
DOTS also calls for a standardized surveillance and monitoring systems.
The overall goal of DOTS is to ensure that TB is cured in diagnosed cases
following an appropriate treatment course, which will also prevent further
transmission as well as the facilitation of drug-resistance.272,273
Many aspects of TB screening of immigrant populations is
controversial. For starters, the use of DOTS as a comprehensive testing
and treatment program has significant costs for countries with a large
inflow of immigrants when the supervised treatment portion of the program
has not been well proven. These findings were consistent with a
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previously published multicenter study of nearly 500 patients in which
three arms were evaluated: 70 were assigned DOTS with direct
observation of treatment by health workers, 165 were assigned DOTS with
direct observation of treatment by family members, and 162 were
assigned self-administered treatment. Outcome measures were cure or
treatment completion. This study found similar outcomes in all three arms
with cure or treatment completion rates of 67%, 62%, and 65%,
respectively. This was an important study that failed to demonstrate
DOTS as a superior strategy over other treatment programs.274 In a
recent retrospective comparative study of 150 patients, the treatment
success rate of 72% was equal in a sample of 75 who underwent
compulsory supervised treatment versus the remaining 75 whose care
was delivered in a self-administered model. Given that DOTS remains
unproven as a superior approach to the administration of TB therapy,
some policymakers recommend its use only after patients fail selfmanagement.275
Many industrialized countries have designed TB screening
programs that are integrated with immigration procedures as a result of
this emerging need. One of the most common screening methods used is
chest radiography for the detection of active disease.276 Applicants
seeking entrance into the US as an immigrant or refugee status are
required to undergo a medical examination prior to their arrival. The
Department of State appoints the physicians who perform the
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examinations according the Technical Instructions provided by the CDC’s
Division of Global Migration and Quarantine (DGMQ). Beginning in 1991,
chest radiography has been used for applicants over the age of 15 years.
Chest x-ray findings suggestive of pulmonary TB were further evaluated
using sputum smears until 2007, when the CDC followed the sputum
smear with cultures. In 2012, 60% of the TB cases diagnosed using
cultures were in applicants with negative smears.
Meanwhile, the universal use of chest x-ray for immigrant screening
has been widely debated in the literature. Most evidence does not support
its use due to unacceptable sensitivity, specificity and costeffectiveness.277 One systematic review and meta-analysis in which 22
relevant publications were analyzed agreed that chest radiograph did not
offer the acceptable yield of an effective screening tool, noting that of the
2,620,739 imaging studies only 5,446 cases of active disease were
diagnosed, representing one diagnosis in 481 chest radiographs.278
Another report noted that among the important diagnostic challenges is
that chest radiography depends on access to complementary resources
such as equipment and the availability of experienced medical personnel
who possess the skills to identify active disease with an atypical
appearance.279 Further, the incidence of false positives secondary to
technical problems, lung scarring, the presence of other underlying
pulmonary disease, or previous TB with associated healed cavitary lesions
is another important driver of program cost. These factors commonly
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result in further medical evaluation and additional costs.280 For these
reasons, untargeted chest radiography has been disproven as part of a
cost effective screening program.
The well documented challenges of diagnosing active TB has
resulted in a lively discussion in the peer-reviewed medical literature and
among policy makers theorizing more effective TB treatment and
diagnostic programs in immigrant populations. This discussion has, in
some cases, resulted in policy changes in some countries. Following a
review of several countries in North America and Europe, it is evident that
a lack of uniformity in screening methods and goals exists in developed
countries. This review implies that no proven standard of TB control exists
that effectively balances TB risk management with cost in immigrant
populations. The most common screening practice is the single-level, one
time screening of migrants for active disease. These largely superficial
and ineffective screening programs remain the most common despite low
yield, which is perhaps the most important measure of program
effectiveness.281
The literature offers a variety of other suggestions for more cost
effective screening programs for immigrant populations. One important
suggestion is to target chest radiography to migrant populations with risk
factors for disease. In this case, imaging may only be recommended for
migrants from moderate to high resource countries or with personal risk
factors for disease. The screening process in Switzerland exists as a
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model for reserving chest radiography for select populations based on
results from a pre-screening interview and associated questionnaire. The
Swiss program utilizes a nurse to conduct the interview in which medical
history and family history are recorded and the results are measured
against the risk associated with country of origin. This program reduces
the number of migrants undergoing chest radiograph based on risk
stratification.282
A 2013 study that evaluated a variety of screening approaches
demonstrated that screening for active disease in immigrant populations is
one piece of what should be multi-faceted program to detect both active
and latent disease. Further, the WHO recommended in a 2014 report that
migrants from high burden TB countries to be screened for latent disease
as well.283 Further, findings from a 2016 review suggest that effective
screening can only be accomplished through multiple, inter-linking
elements including pre-arrival screening of active disease in addition to
post-arrival screening of latent disease targeted to migrants from
moderate to high burden TB countries. The authors acknowledge
considerable challenges with the implementation of a multi-level program,
but urge more research in TB screening program design and effectiveness
in order to better establish international evidence based guidelines.284
Given that the presence of latent disease is another important
pathway to infection for immigrant populations, some policy makers have
also suggested immigrant screening for latent disease. However, few
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studies have been published that analyze the effectiveness of screening
programs for latent disease.
TB skin testing (TST) has been the screening tool of choice for a
variety of settings including but not limited to healthcare and restaurant
workers in addition to immigrant populations. The majority of the limited
data evaluating the potential utility of latent disease screening programs in
immigrant populations relies on the TST. A study of refugee populations
evaluated the impact of screening for latent disease using a TST prior to
entrance into the United States as a means of reducing the incidence of
active TB in this population. This was a cost benefit study using a
decision tree with multiple Markov nodes to determine the total costs and
number of active TB cases in 55, 35, and 20% TST positive under two
models: no overseas screening and overseas screening and treatment.
Also, refugees were stratified by risk based on the prevalence of TB in
their country of origin into the following categories: high, moderate, and
low TB. Using the hypothetical 100,000 refugees over a one year period
from countries with high, moderate, and low TB prevalence, the authors
estimated that screening for latent TB would prevent 440, 220, and 57
cases in the US during the first 20 years after arrival. Further, the authors
emphasized a cost savings associated with the screening program of $4.9
million for refugees from high burden TB countries when the cost of
treatment was considered, $1.6 million for countries with moderate TB
prevalence, and $780,000 for low TB prevalence countries. The authors
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noted that these cost savings were conservative given that the cost of
managing additional cases secondary to the transmission of active TB
from these cases was not considered in this model.286
One important consideration of screening for latent TB is the
several functional challenges surrounding the use of the TST. First, the
test is read between 48 and 72 hours following administration, which
requires a separate visit. Also, the reading of results may be open to
interpretation.287 The other potentially critical challenge is relying on the
TST especially when screening immigrants from high burden TB countries
is previous exposure to the Bacillus Calmette–Guérin (BCG) vaccine. In
many high burden TB countries, the BCG vaccine is administered to
babies as a population level prevention strategy.288 In fact, the WHO
recommends that BCG be administered to all children born in high burden
countries.289 In low and moderate burden countries, the use of BCG
vaccine is targeted to at risk populations. Babies in these populations are
sometimes vaccinated. Adults can be vaccinated as well. The vaccine
protection timeframe is between 10 and 20 years.290 One major
consideration, however, is research indicates that exposure to the BCG
vaccine can generate a false-positive TST. Also, those with active NTM
infection are likely to yield a false positive result.291,292 Further, TST may
generate false negatives in hosts who are pregnant, or
immunosuppresses due to malignancy, nutrition, HIV/AIDS, or those
receiving immune modulating therapy given the reliance of the TST on the

85

ability of the immune system to generate a response.293,294,295
Another important screening tool for latent disease are IFN-gamma
release assays (IGRAs). Currently, two blood assay tests are
commercially available: Quanti-FERON-TB Gold In-Tube (QFT-GIT;
Cellestis, Carnegie, Australia) whole blood enzyme-linked immunosorbent
assay (ELISA), and the T-SPOT.TB assay. Limited data are available that
compares TST with assays in migrant populations, noting that QuantiFERON-TB seems to have a lower detection rate than the T-SPOT.TB
assay. It is important to note, however, that both assays seem to be less
sensitive than TST.296 Also, few data are available to evaluate the use of
IGRAs as a screening tool, but emerging data indicates that blood assays
are not reliable in this setting, especially in cases in which latent disease
has been previously treated or there has been a history of TST.297
In a master’s thesis, the cost effectiveness of screening tools
including TST and blood assay tests for latent infection were evaluated in
the Netherlands, a low burden TB country, in immigrant populations who
participate in contact investigations. Using decision tree analyses that
measured direct medical costs for two years following screening for latent
disease, this study measured two years of cost analyses following initial
contact investigation in which the use of TST was validated in healthy
immigrant contacts.298
Perhaps the most important component of a successful screening
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program for latent disease is the ability to provide and complete treatment
in positive cases. This depends on two primary factors. First, adequate
public resources need to be allocated to provide treatment in all cases of
latent infection. Second, a concentrated effort is necessary in order to
assure that immigrant populations remain compliant during long treatment
courses. This remains a particular challenge given that these populations
tend to be vulnerable and not always able to comply with office visits and
medication. Also, in many migrant populations people move frequently,
which requires a transfer of care during long treatment courses, which
increases the likelihood of patients discontinuing therapy. Further, cultural
issues in many populations play an important role. In a study of Hispanic
migrant farm workers entering the US, adherence to treatment was found
to be an important challenge noting that less than half agreed to even
initiate therapy citing cultural barriers.299
These programs all share an important limitation in that they are
confined to a screening population of migrants that legally enter
destination countries and submit to the legal entry process. Population
screening is not available for the thousands of migrants who enter
destination countries illegally.300 The Department of Homeland Security
estimates 11.4 million unauthorized immigrants were living in the United
States on January 1, 2012. This figure has not significantly changed from
the January 1, 2011 estimate of 11.5 million.301
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Nontuberculous Mycobacterium
Nontuberculous Mycobacterium (NTM) represents an emerging
public health challenge. In the developed world, NTM infection rates have
risen significantly in recent decades secondary to many factors including
population aging, the availability of immune suppressing therapies in
resource rich healthcare delivery systems secondary to cancer,
autoimmune disorders and post-transplant therapy. Also the worldwide
HIV/AIDS epidemic continues to facilitate the prevalence of NTM in the
developed world as well as the undeveloped world. Even so, cost
information measuring direct and/or indirect costs as well as economic
impact remains extremely under measured. The few available studies that
attempt to describe the cost of care of NTM in limited care settings note
the lack of data available and encourage other research in this largely
unappreciated global health crisis. In the undeveloped world, even less
data are available regarding all aspects of NTM including epidemiology
and cost. The majority of discussion on NTM in the developing world
addresses the disease as it impacts the diagnosis and treatment of TB.
These studies emphasize the challenge of appropriate treatment for TB in
high burden clinical settings when the potential confounding case of NTM
presents.
NTM in the underdeveloped world
The epidemiology and cost of NTM in the developing world is an
emerging area of research in the field of mycobacteriology. Many
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important challenges exist that has made research in this area difficult.
For starters, mycobacterial disease is diagnosed in developing countries
based on clinical and radiological findings.302 Diagnostic technology is not
usually available in these care settings that would differentiate NTM
species from TB or other diseases. Given that NTM often resembles TB
in disease presentation and radiological features, many researchers
believe that NTM is often mistaken for TB, particularly MDR-TB, following
a treatment failure. This theory has important implications for resource
management in low resource care settings as well as antibiotic
stewardship. For these reasons, no estimates of NTM rates in low
resource countries are currently available. What little data exists must be
pieced together from studies conducted of TB in low resource countries in
which the discovery of NTM is incidentally reported.303 No cost
information is available except also in cases in which NTM was
misidentified and noted to impact the cost of treatment.
Emerging literature is addressing the burden of NTM disease in low
resource countries as its clinical importance relating to other health
challenges in these care settings has become increasingly apparent.
First, the association of NTM with the HIV/AIDS epidemic is well described
in most every care setting. The importance of this relationship is amplified
in developing countries in sub-Saharan Africa in which HIV/AIDS rates
have been reported as high as 25%. Further, the unavailability of
important therapies that have been shown to slow down or stop the
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progression of HIV to AIDS in many low resource care settings is also an
important contributor to the epidemiology of NTM. In a 2007 dissertation
in which NTM was studied in Zambia, one of the world’s poorest countries,
this particular study emphasized the importance of HIV/AIDS as a risk
factor for NTM in Zambia as well as neighboring countries in the region.
This dissertation featured a study population of 64 patients of mixed HIV
status who had been chronically ill for more than two weeks, thirty of
which were identified as infected with mycobacterium disease using liquid
culture. Only eight patients from this sample were found to be infected
with TB as compared to twelve who were infected with NTM. Of the NTM
species identified, seven patients were diagnosed with M. szulgai, three
patients had MAC, one patient had M. simiae and the remaining one
patient had M. terrae. One interesting finding of this study was the
presence of M. szulgai, which represents an NTM species that strongly
resembles TB in disease presentation as well as DNA. In this particular
sample, five patients with NTM disease caused by M. szulgai were given
anti-TB therapies and three cases were noted as responsive. It is also
important to note that ten isolates in this study were unable to be
identified. The major conclusion of this study was that TB is grossly over
diagnosed in Zambia, which must be addressed by improving access to
better diagnostic technology as well as the incorporation of diagnostic
scoring systems and algorithms to be validated for use in low resource
countries with a high burden of TB and HIV/AIDS as diagnostic support
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tools.304
In a study conducted in the high burden TB country Mali where
most patients receive empiric treatment for TB, clinical samples from 142
patients were evaluated by smear, culture and drug susceptibility testing.
This study had two arms: 61 patients who had undergone treatment for TB
and 17 patients who had no previous exposure to anti-TB drugs. Of the
11 patients who tested positive for NTM, all were identified from the
treatment experienced group. It is important to note that all 11 candidates
had been identified as candidates for expensive second line anti-TB
treatments.305
In low resource countries with reliable access to laboratory
diagnostics, the low cost option of sputum smears remains widely used.
The issue with smears, however, is that TB and NTM cannot be
differentiated without follow up studies including cultures or molecular
methods of species identification.306 In China, 80% of laboratories
designated for TB diagnostics lack the equipment necessary to perform
culture or other methods of species identification leading to a diagnosis of
NTM infection.307 The misdiagnosis of NTM infection has important global
consequences, leading to inappropriate treatment, elevated cost, and the
facilitation of continued antibiotic resistance.
In a study conducted in Tehran, Iran, sputum smear and culture
were performed on clinical isolates collected from 105 patients.
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Microbiological testing was repeated twice to assure accuracy. Also, PCR
was performed on all patients and species identification was performed by
PCR and routine identification tests for all culture-positive cases. In this
study, 12 isolates, (11.43%) were identified NTM species. It is important
to consider that clinical appearance was similar in patients. For example,
cavitary lesions were present in 41.7% of the cases.308
Another study conducted in the southwest portion of Iran was a
retrospective evaluation of 117 consecutive samples collected from
patients diagnosed with MDR-TB. Patients who met criteria for inclusion
had been administered between two and three months of a first line antiTB regimen but had not achieved sputum conversion. A total of 35
patients in this sample had isolates that were identified as an NTM
species, and 32 of these patients met American Thoracic Society (ATS)
and the Infectious Diseases Society of America (IDSA) criteria for active
NTM disease. Underlying disorders that represent risk factors for NTM
were present in 32 patients and included active malignancy, organ
transplantation, HIV, chronic renal failure, and diabetes mellitus. Only
three patients diagnosed with NTM in this study had no known risk factor.
This study also evaluated clinical outcomes for 27 patients retrospectively
identified with NTM for which this data was available. Ten patients were
noted to have poor outcomes, six of which were documented as treatment
failures and four died during the treatment course. The remaining 17
patients for which outcome data was available was noted as cured,
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although the authors admit that outcome data was difficult to ascertain and
is likely inaccurate. The importance of this study is that it demonstrated
that NTM was identified in 30% cases that had been misdiagnosed with
MDR-TB, which represents a figure that is higher than the previous reports
from Iran. It is also important to note that given this study being limited
only to MDR-TB cases, the case of mistaken identity in mycobacterial
diseases is likely a much bigger problem than current literature has
proven. The authors of this study ask an important question, is MDR-TB
really NTM?309
A study conducted in Nigeria found that of the 1603 patients with
assumed TB, only 444 yielded a positive culture result following laboratory
microbiological studies. Of these, 69 isolates were found to be infected
with NTM. This study also found that NTM was more frequently
diagnosed during the season of the year characterized by the presence of
dust, validating environmental exposure as an important transmission
pathway. Also, the presence of NTM infection in younger hosts was
frequently associated with the presence of comorbid HIV/AIDS as
compared to those older than 35 years.310
The burden of NTM in low resource countries has been studied
mostly in the context of identifying functional barriers in the appropriate
management of TB. Due to the similarities in symptomology coupled with
the difficulty of diagnostics when relying merely on smears, the two are
easily confused in low resource settings, leading to improper treatment,
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increasing costs and facilitating further drug resistance. See the table
below for a summary of NTM studies from the underdeveloped world.
Table 10: NTM studies in the underdeveloped world
Author(s) Setting
Buijtels, P Zambia
(doctoral
dissertation)

Maiga et
al.

Mali

Tabarsi et
al.

Tehran,
Iran

Shahraki
et al.

Southwest
Iran

Aliyu et al.

Nigeria

Study Type
Laboratory
based using
liquid culture
Laboratory
based:
smear,
culture, DST
Laboratory
based using
culture and
PCR
Laboratory
studies
conducted
on patients
diagnosed
and treated
for MDR-TB
Laboratory
based using
culture

Study Size
64 patients
with mixed
HIV status
142 patients:
61 treatment
experienced;
17 treatment
naive
105 patients

Findings
30 Mycobacterium;
8 TB; 12 NTM

117 patients
who had not
improved
after 2-3
months of
anti-TB
therapy,
1603
patients
diagnosed
clinically with
TB

35 patients with
cultures positive
for NTM, 32 met
ATS/IDSA criteria
for infection

11 patients
diagnosed with
NTM, all from
treatment
experienced group
12 patients
diagnosed with
NTM

TB: 444 patients;
NTM: 69 patients

NTM in the developed world
The relationship between TB and NTM in the developed world has
been dynamic in recent years. While TB rates in North America, Europe
and parts of Asia have been steadily declining, the prevalence of NTM
disease in the same care settings has exploded. To illustrate, NTM
infection prevalence in North America was estimated to be between 1.6
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and 1.8 per 100,000 in the 1980s, with reports published in 2007
estimating prevalence of 14.1 per 100,000.311 It is likely that this number
is even greater. A 2014 study sought to establish the relationship
between NTM and TB in different care settings all over the world. A total
of 16 regions were evaluated including areas in Canada, the US, western
Europe, Australia, Greece, Czech Republic and Japan, and the decline of
TB alongside the incline to NTM was noted in the majority of regions
based on data published in 22 studies. The authors offered several
theories for this relationship. First, the existence of some degree of crossimmunity between different mycobacterial species could be a
consideration if both diseases were affecting similar populations. Given
that TB and NTM affect characteristic populations that do not intermingle;
this explanation does not explain the trend particularly in North America
and Europe. Another theory is related to stages in modernization. In
North America and Europe, some of the causal elements that created a
surge in TB rates in the nineteenth century urban crowding and issues
with sanitation secondary to industrialization. In many of these modern
cities, significant progress has been made to improve urban crowding and
sanitation with improvements in ventilation and public water delivery
systems. Given that NTM species have been confirmed in a variety of
water samples including municipal water pipes and can be theoretically
transmitted through aerosolized water from showers and hot tubs, it is
conceivable that modern advances particularly in water delivery systems
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have facilitated the transmission of NTM. Of course, improvements in
laboratory methods that may have misdiagnosed NTM as TB may also
play a critical role. Also, population aging and the age of immunecompromising conditions and drug therapies also play an important
role.312 Finally, the worldwide HIV/AIDS epidemic has had an impact on
the prevalence of disease in the developed world as well as North
America and Europe.313
NTM and Cost
A total of four studies have been published that attempt to measure
the cost of NTM infection in western care settings. In the United States, a
small cohort study of 27 patients with pulmonary NTM found an annual
antibiotic therapy cost of $5,196 for those infected with MAC and $11,796
for M. abscessus. The median total per patient drug cost was reported at
$19,876 Also emphasized in this study, the cost of treating different types
of NTM species can fluctuate due to variations of antibiotic cost. For
instance, M. abscessus was noted to be associated with higher treatment
cost as well as the use of intravenous antibiotic therapy over oral.
Ballarino noted that given cost data is limited in the literature for NTM, the
use of a more established disease such as HIV/AIDS given its chronicity
and high medication cost might be an effective proxy for NTM.314
A retrospective chart review was conducted in Ontario, Canada of
pulmonary NTM to determine outpatient treatment costs in Canada.315 Of
the 177 patients identified in this study, costs were calculated for the 91
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who underwent treatment for an average duration of 14 months.
Researchers found that annual cost was $5,000 in Canadian currency
adjusted to 2008 value and antibiotics were responsible for 70% of total
cost. It is also important to consider that over 40% of patients had been
diagnosed with pre-existing COPD, and an even higher proportion of
patients had been diagnosed with obstructive airway disease. Also noting
the unavailability of cost data for NTM, Leber and Marras suggest using
diabetes mellitus as a proxy for measuring cost.316
Perhaps the most comprehensive studies currently available are
the two that used national data to estimate and report national
epidemiological and cost data. The first is a state specific population
based study using Medicare data along with national survey data. Strollo
and researchers used a 5% sample size of the Medicare Part B database
during the years 2003 through 2007 in order to establish an annual
prevalence, and applied these averages to census data from 2010.
According to this study, an estimated $815 million was spent on NTM care
in 2010, 87% of which was spent on hospitalizations and 13% on
outpatient management. This study also estimated that 76% of direct
medical costs was used for antibiotic therapy. Given that this data would
only include Americans over the age of 65 years, this study relied on
previously reported epidemiology in peer-reviewed literature in order to
estimate the number of cases in this age group. Cost was also estimated
based on figures reported in other studies and adjusted to the 2014 value
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of the U.S. dollar. Further, cost figures reported in this study only included
one medical encounter per year per patient. For inpatient estimates, cost
would only include one hospitalization, which may be incomplete given
that NTM infection has high rates of recurrence and other complications
that often result in readmissions. For outpatient data, this study only
included one NTM-related visit per patient per year, which is more likely to
be incomplete given the chronic nature of NTM infection and its
requirement of routine outpatient visits. Also, the need for close
monitoring of patients undergoing treatment for NTM is necessary in order
to both measure treatment success and identify adverse reactions quickly
that are common during an NTM treatment course. Although this study
boasts of being the very first to provide state level NTM epidemiological
and cost data, the figures reported represent merely estimates that are
likely significantly lower than actual figures. Despite this, the value of this
study is its demonstration of NTM as a substantial disease burden with
high financial costs.317 Another national study measured epidemiological
data and cost associated with the management of ten waterborne
diseases. The most common pathogens in this study associated with
disease were NTM along with giardiasis, cryptosporidiosis, Legionnaires’
disease, and otitis externa. This study used national data available from
the CDC that included claims data from Medicare and Medicaid for the
most recent two-year period available during the study period. Medicare
data available through the CDC was accessed through Marketscan® and
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was available for the years 2006 and 2007. Multi-State Medicaid
databases were available through the CDC from Thomson Reuters from
the years 2004 and 2005. From 3,684 hospitalizations and 341,157
outpatient visits, NTM was found to be among the most important of
waterborne disease representing the cause of disease in 21% of
immunocompromised patients, second only to cryptosporidiosis at 24%.
Patients with NTM had the longest reported hospital length of stay at an
average of 10.5 days. Also, pulmonary NTM was the most expensive
disease to manage in an outpatient setting with collections ranging from
$311 from Medicaid patients to $1848 for patients with commercial
insurers. These values represents the amount collected from payers per
visit. Also, NTM represented the second highest average hospitalization
cost with pulmonary infection collections ranging from $12,725 for
Medicaid to $37,579 for commercial insurance per episode. For
pulmonary NTM, this study recorded a total of 22,210 cases, 14,210
(65%) were managed in an outpatient setting with the remaining 7,659
(35%) represent hospitalized patients. The average hospitalization
collection reported in this study was $25409, and the average outpatient
cost was $1374. It is important to note that this figure did not include
laboratory testing costs. The purpose of this study was to highlight the
significance of waterborne disease given the near-universal exposure to
multiple water sources that can lead to significant costs in the event of a
community-wide outbreak. However, this study had several important
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limitations. First, many of the diseases evaluated have several routes of
transmission so the impact of waterborne diseases remains unproven. As
is the case with most studies, measuring the total economic burden of
diseases that includes mortality and disability, work and time loss, and
chronic sequelae are difficult to measure, so this study that seeks to
establish the costs of direct medical care only will always be incomplete.
In this particular study, some aspects of direct medical costs had to be
estimated as some outpatient data was unavailable. Also, this study was
limited to patients with Medicare and Medicaid as payers for outpatient
data, which has important patient selection implications for age and
demographics.318
Currently available data is limited to four studies that measure
some aspects of direct cost for pulmonary NTM using data obtained from
different care settings and patient populations. Also, these costs are
represented in different currencies and inflationary values. As a result,
cost findings for all four studies have been represented as an average per
patient cost value and adjusted to US currency using Google currency
converter319 and 2016 value using the Consumer Pricing Index calculator
available through the US Bureau of Labor and Statistics.320 These
findings are outlined in the table below.
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Table 11: NTM and Cost in the Peer Reviewed Literature
Author(s),
Year of
Publication
Ballarino et
al. 2009

Setting

Study Size

Cost Findings

Average Cost
per Patient

US

27 patients

Leber and
Marras
2011

Canada 177 patients

$19,876
(USD, 2008)
$22,315.55
(USD, 2016)
$4916 (CAD,
2008)
$4109.44
(USD, 2016)

Strollo et
al. 2015

US

National
Medicare data,
2010
86,244 patients

Collier et
al.
2012

US

National
inpatient
sample,
Medicare,
Medicaid
7,659
hospitalizations,
14,551
outpatient

$5,196 for MAC
and $11,796 for
M. abscessus
Antibiotics alone
$4,916 for
outpatient
treatment, 70%
of total cost was
antibiotics
$815 million total
in 2010, 87%
hospitalizations
and 13%
outpatient,
antibiotics
accounting for
76% of total cost
Average costs:
$1374 outpatient
(65% of cases)
and $25,409 for
hospitalizations
(35% of cases)
for pulmonary
NTM

$9453.22
(USD, 2014)
$9,652.60
(USD, 2016)

$9.786.75
(USD, 2007)
$11,409.27
(USD, 2016)

Other presentations of disease such as dissemination or bone and
joint infection site can actually be more costly to treat. The Collier at al
study does offer some limited data on general NTM infection, but does not
define the site of infection. Also reported in this study is limited cost data
for disseminated NTM infection. Unlike the body of literature measuring
various aspects of TB and cost, similar data is unavailable that measures
indirect costs and economic impact of NTM infection.
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Literature Gap
NTM is an emerging public health problem in the US and the world
for which very little has been published in the current body of literature.
Also, given that NTM is not a reportable disease in the US, rates of
infection are estimated and pieced together from various sources as no
central epidemiological or surveillance data exists. In other developed
countries, the burden of the rising rates of NTM infection is likewise not
understood. In the developing world, NTM is largely ignored and likely
managed as TB, and is in many cases retreated as MDR-TB following a
treatment failure. The distribution of NTM in low resource countries with
high burden TB prevalence remains unknown. Meanwhile, cost
information for the management of NTM in North America is based on
data published in four available studies. These studies offered a picture of
direct medical costs for the outpatient management of NTM. No cost data
is available from Europe, Australia, or developed countries in Asia. In the
developing world, no data measuring cost or economic impact of NTM
infection exists. This lack of information exists alongside the mountains of
published literature describing most every aspects of cost for TB in various
countries including the industrialized west as well as developing countries
in Africa, Asia and Latin America, and in various care settings.
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CHAPTER 3: RESEARCH METHODS
The rising cost of healthcare is an important field of interest in most
every economy as balancing resource constraints with demand has
become a common challenge in both developing as well as industrialized
countries. Understanding drivers of cost whether they be related to
incidence or high treatment and technology costs has also become critical
in resource management. Further, the presence of trends in cost implies
similar trends in disease incidence and associated management costs,
which has important implications for scientific interest and policy
interventions. Given the lack of information available in peer reviewed
published literature and national databases, Nontuberculous
mycobacterium (NTM) disease remains an emerging field of research as
little information is available regarding epidemiology and cost in virtually
every care setting. Despite this, the importance of NTM as a medical
problem and cost driver remains undocumented. Meanwhile, a myriad of
data is available for Mycobacterium tuberculosis (TB) that qualifies this
disease as a worldwide public health crisis, especially in select developing
countries.
This study was designed to add to the small knowledge base of
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NTM, most specifically the cost and economic impact of this emerging
public health challenge. The cost and trends in cost of pulmonary NTM
were evaluated in the context of similar data that was ascertained for
pulmonary TB for hospitalized patients in the US over a long study period,
from 2001 to 2012. Additionally, this study sought to better understand
demographic features of this disease as well as define and compare, and
contrast social determinants of mycobacterial infection using national
population level data. Finally, clinical measures were recorded and
evaluated comparing the impact of morbidity and mortality of pulmonary
disease caused by NTM and TB.
Study Goals
The primary goal of this study is to conduct a comprehensive
evaluation of the costs of care for pulmonary TB and NTM in US in-patient
hospital settings using national data during a long study period beginning
in 2001 through 2012. The secondary goal of this study is to document
cost data as well as identify important trends that may provide insight into
future projections and challenges, as well as document the similarities and
differences between these two diseases in demographic features, socioeconomic status and clinical outcomes.
Specific Aims
This study has two very specific aims. The first aim is to provide an
accurate cost comparison of pulmonary disease caused by NTM and TB.
The second aim is to identify and compare trends in cost, demographic
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features and clinical outcome data of hospitalized patients with pulmonary
NTM and TB.
Hypothesis
Current published medical literature provides significant insight into
the epidemiology and cost of managing TB from various care settings all
over the world. Only a small percentage of this data is available for NTM
infection, most of which is confined to care settings in North America.
Based on published findings for both diseases, the expected results from
this study include the identification of increasing rates of infection and
related costs associated with the management of pulmonary NTM
infection alongside flat or declining rates of pulmonary TB infection for
hospitalized patients in the US. Additionally, characteristic patient
demographics for pulmonary TB infection including young males of lower
socio-economic status as well as older females of higher socio-economic
status for pulmonary NTM infection are expected to be found following
review of this population-based national dataset.
An alternate hypothesis is NTM rates and costs are represented by
only a mild increase, which might be explained by the small amount of
data currently available representing a sample that is not characteristic of
population level national data. Another explanation might be the limitation
of scope in this study in which only hospitalized patients were considered,
or that only select NTM pathogens could be included.
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Regardless of outcome, important implications for future research
and policy implications can be extrapolated, including the continued
worldwide investment in TB control and the increase in resources required
for NTM control and research that may lead to better detection and
appropriate treatment in all care settings.

Methods
This is a retrospective, population based comparative study using
data obtained from the National Inpatient Sample (NIS) available from the
Agency for Healthcare Research and Quality’s Healthcare Cost and
Utilization Project (HUCP). NIS is the largest inpatient healthcare dataset
in the US providing national estimates of hospital costs stratified by
disease. NIS collects data from every state participating in HCUP, which
includes more than 95% of the US hospitalization data.321 All patients with
a principal diagnosis of pulmonary NTM due to M. avium, M.
interacellulare and M. kansasii and pulmonary TB who were discharged
from the hospital during 2001 through 2012 were included in this study.
This study was submitted to the University of Louisville Institutional
Review Board, where it was determined that the data reviewed in this
analysis did not meet the definition of human subjects and did not require
a review from the ethics board in order to proceed. The outcome letter for
IRB study submission number 16.0828 has been included in the appendix.
Study definitions
This study includes both disease related definitions as well as
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geographical features, payers and other socio-economic indicators and
clinical measures. Pulmonary NTM was defined by any hospital discharge
associated with principal diagnosis of an International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9) code 031.0. This
diagnosis code includes pulmonary infection caused by M. avium, M.
interacellulare and M. kansasii. The Principal diagnosis was defined as
the main reason for admission. The regions of the US were classified into
four zones recognized by Bureau of the Census as Northeast, Midwest,
South and West as outlined below in Table 12.
Table 12: Census Bureau Classification of the US by zone

Zone

States
Connecticut, Maine, Massachusetts, New Hampshire, New
Northeast Jersey, New York, Pennsylvania, Rhode Island, and
Vermont
Illinois, Indiana, Iowa, Kansas, Minnesota, Missouri,
Midwest Michigan, Nebraska, North Dakota, Ohio, South Dakota
and Wisconsin
Alabama, Arkansas, Delaware, District of Columbia,
South
Florida, Georgia, Kentucky, Maryland, Mississippi,
Louisiana, Tennessee, North Carolina, Oklahoma, South
Carolina, Texas, Virginia, and West Virginia
Alaska, Arizona, California, Colorado, Hawaii, Idaho,
West
Montana, Nevada, New Mexico, Oregon, Utah,
Washington, Wyoming
Several variables were defined, collected, and analyzed in this
study related to disease severity, demographics and socio-economic
status. Hospital length of stay was defined as the number of days the
patient remained in the hospital. Payer was classified by the type of
insurance coverage carried by the patient or lack thereof, which included
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Medicare, Medicaid, Private insurance (Blue Cross, commercial carriers,
and private HMOs and PPOs), uninsured which includes an insurance
status of "self-pay" and "no charge", and Other which includes Worker's
Compensation and other government payers. Median income was
defined as the average household income of patient zip code of residence
and compared with national median income for the same year. HCUPnet
used value ranges of the average household income itemized by year.322
Table 13: Annual ranges for calculation of median income by zip code

Year

Low

Middle or Above

2003

$1-35,999

$36,000+

2004

$1-35,999

$36,000+

2005

$1-36,999

$37,000+

2006

$1-37,999

$38,000+

2007

$1-38,999

$39,000+

2008

$1-38,999

$39,000+

2009

$1-39,999

$40,000+

2010

$1-40,999

$41,000+

2011

$1-38,999

$39,000+

2012

$1-38,999

$39,000+

Study variables
Several variables in this study were evaluated; including age group,
gender, region, payer, median income according to zip code, hospital
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length of stay in days, mean hospital charge per admission, mean
aggregated charge, total aggregated charge, and in-hospital deaths.
Statistical Analysis
The statistical significance of observed trends of NTM and TB
national hospital costs were calculated using Poisson log-linear
regression. National hospital costs for NTM and TB were projected in
relation to health care inflation for each year. Expected mean aggregated
charge (EaC) was calculated based on health care inflation using the
equation, (EaC= Hci x OaC), in which EaC is expected aggregated
hospital charge, Hci is health care inflation percent for each year (Hci =
total aggregated hospital charge for a specific year divided by the total
aggregated hospital charge for prior year ×100) and OaC is the observed
aggregated charge for each medical condition. A regression model was
applied to test the correlation between observed and projected aggregated
hospital charges, otherwise known as national hospital costs. All
statistical analyses were performed using SPSS statistical software
(version 21.0, IBM Corporation)
Results
This study included an evaluation of 36,484,846 hospital
admissions in the US from 2001 through 2012. A total of 20,049 hospital
discharges were reported for pulmonary NTM and 44,370 for pulmonary
TB in the US from 2001 through 2012. Using national data, this study
measured numerous variables including demographic, cost and clinical
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factors impacting the distribution of disease in the US. The findings from
this study have important implications that both validate and expand the
findings from other research.
Demographic findings
This study sought to explore demographic features of
mycobacterial diseases in the context of new findings as well as published
literature. A number of demographic features of patients with pulmonary
NTM and TB were measured including age, gender, payer status and
estimated household income. Demographic features of both diseases
have been previously described relative to clinical and socio-economic
importance, and the results of this study validated previous findings.
The variation of age distribution for pulmonary mycobacterial
diseases is well described in the literature. These variations were also
noted in the results of this study. The majority of pulmonary NTM patients
were between 65 and 84 years old (48.5%), while 70% of TB patients
were younger than 65. These findings were consistent with other studies
as the association of NTM with older patients and TB with younger
patients is well described. When evaluating the over 65-age group
specifically, a statistically significant difference was found between the
NTM and TB group (P=0.0001) as well as the very elderly (+85)
(P<0.00001, OR=2.83). TB was also more common in pediatric
populations than NTM, with 5.1% of hospitalized patients with TB
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occurring in children 17 years and younger versus 1.2% of the population
of hospitalized patients NTM occurring in children. The table below
illustrates the age distribution for each disease.
Table 14: Age distribution of pulmonary NTM and TB

Age Group

NTM (%)

TB (%)

<17 (pediatric)

1.8

5.1

18-44

7.6

36.3

45-64

31.3

33.8

65-84 (elderly)

48.5

20.7

>85 (very elderly)

10.8

4.1

The distribution of disease by gender demonstrated statistically
significant differences between NTM and TB. As described across
studies, the relationship between TB and males along with that of NTM
and females are well described in the currently available medical
literature. Pulmonary NTM was significantly higher in females than
pulmonary TB (P<0.00001) and pulmonary TB is much higher in males
than females. See the table below for the distribution of NTM and TB by
gender.
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Table 15: Gender Distribution of pulmonary NTM and TB

Gender

NTM (%)

TB (%)

Male

44

67

Female

56

33

One particularly interesting finding of this study is the geographical
distribution of TB and NTM appear almost identical. Both diseases were
most common in the region defined as the South, representing 43% of
cases for both diseases. One explanation for this finding is that warm
and humid climates may facilitate the transmission patterns of both TB
and NTM similarly. The next most common region was the West, which is
also characterized by a warmer climate as compared to other regions in
the US. A total of 22% of NTM cases and 23% of TB cases resided in the
West. The Northwest represented the third most common region for NTM
and TB at 19% and 21%, respectively. Both diseases were least common
in the Midwest. These data indicate that all pathogenic mycobacterium
species may be impacted by the same environmental factors that drive
disease transmission. See the table below for the distribution of disease
by geographical zones.
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Table 16: Geographical distribution of pulmonary NTM and TB

Region

NTM (%)

TB(%)

Northwest

19

21

Midwest

16

13

South

43

43

West

22

23

Payer status was evaluated for TB and NTM admissions and the
findings had several important implications. The most significant
difference in payers noted in the two groups was Medicare, representing
61% of pulmonary NTM inpatient costs as compared to only 24% of the
hospital costs of subjects with pulmonary TB (P<0.00001). Given that
NTM is associated with disease in older populations, the discovery that
Medicare was the primary payer for NTM hospitalizations was expected.
Medicare comprising 24% of TB admissions was higher than expected,
but following reconciliation with the age distribution findings in this study
these results were consistent with other findings from this study. One
explanation with the higher than expected percentage of TB patients from
this age group may be a result of the baby boomer cohort occupying a
large proportion of the population, which may amplify the distribution of
less common diseases in this age group. The association of TB with
Medicaid and the uninsured, however, was fully expected given that these
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payer statuses are strong markers for the poor, immigrants and other
vulnerable populations. The stronger association between NTM and
private insurance was expected, implying a higher socio-economic
association with NTM infection as reported in multiple studies. See the
table below for the distribution of disease by payer status.
Table 17: Payer status of pulmonary NTM and TB

Payer

NTM (%)

TB (%)

Medicare

61

24

Medicaid

10

23

Private insurance

22

19

Uninsured

5

25

Other

2

9

Missing

2

3

For the purposes of this study, household income was defined by
the average annual income of the zip code where the patient resided
according to hospital admission records. Income levels were defined by
two variables: low and average or above. These averages were adjusted
annually based on inflation as outlined in Table 13. Zip code analysis
confirmed the association of NTM and higher socio-economic status as
72% of NTM patients were defined as middle income or above. This
finding was in contrast with the demographics of patients with TB in which
only 55% were considered average or above. Only 26% of pulmonary
NTM patients had a household income that was considered low as
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compared to 41% for patients with pulmonary TB (P=0.0246, OR=0.51).
These findings are consistent with those from other reports. See the table
below for disease distribution by median income based on zip code.
Table 18: Median income by zip code in patients with pulmonary NTM and
TB

Median income for Zip Code

NTM (%)

TB (TB%)

Low

26

41

Middle or Above

72

55

Missing

2

3

Cost findings
Perhaps the most important finding of this study lie in the cost
figures collected over the duration of eleven years, beginning in 2001 and
continuing through 2012. First, the total hospital cost for all conditions
recorded during the study period was $1,337,939,745,325. Pulmonary
mycobacterial diseases accounted for a total of $2,981,880,609, which
represents 0.22% of all hospital costs during the study period. Hospital
cost due to pulmonary NTM was found to be $903,767,292, which
represents just over 30% of mycobacterial diseases diagnosed during the
study period. Hospital cost due to pulmonary TB was calculated at
$2,078,113,317, which represents nearly 70% of mycobacterial diseases
recorded during the study period. See the table below for an illustration of
hospital cost due to mycobacterial diseases from 2001 to 2012.
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Table 19: Hospital charge due to mycobacterial diseases

Indication

Cost ($)

Mycobacterial Diseases (%)

NTM

903,767,292

30.3

TB

2,078,113,317

69.7

The average hospital charges per admission were similar for both
NTM and TB. The mean aggregated charge describes the actual average
annual hospital charges for both diseases, as opposed to the expected
mean aggregated charge, which is a multiplier of actual hospital charges
and healthcare inflation. The expected mean aggregated charge was
lower for both diseases than actual charges, which implies that trends for
both diseases did not meet expectation in charges during the study period.
However, these values are annual averages and do not reflect trends
observed for both diseases during the study period. Also listed below is
the mean aggregated collection. This figure is estimated based on
assumed rates of collection for each payer. These assumptions are
based on industry averages which include the following: Medicare is 45%,
Medicaid is 35%, private insurance is 55%, uninsured is 20%, and other
and missing are estimated at 30%. The overall average collection rate for
NTM was estimated at 45% and for TB this rate was estimated at 37%.
Please note that actual figures are not available as collection data are
considered proprietary contractual information.

116

Table 20: Cost figures for patients with pulmonary NTM and TB

Variables

NTM

Mean hospital charge per admission
($)
Mean aggregated charge ($)

47,120

TB
48,332

80,886,935 246,398,995

(OaC)
Expected mean aggregated charge ($)
(EaC)

85,005,570 282,501,149

Estimated mean aggregated
collections ($)

21,322

17,859

Effective collection rate (%)

45

37

Trend analysis in this study reflects a different result. National hospital
charges for pulmonary NTM increased at a statistically significant rate
each year (P=0.001). A linear regression analysis demonstrated a high
degree of correlation between NTM observed and projected national
hospital costs (R=0.938, P<0.001). This finding predicts that NTM is on
an upward trajectory that will likely continue to increase in coming years.
However, no such correlation between observed and projected national
hospital costs was found for pulmonary TB (R=0.284, P=0.372). In fact,
TB rates of infection appeared to increase, but did so at a rate less than
healthcare infection. Annual averages were likely impacted by movement
early during the study period that did not maintain over time. See the
figure below for a representation of cost trends for mycobacterial diseases
relative to health care inflation.
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Figure 6: Mycobacterial diseases cost trends
Epidemiological trends identified NTM and TB over time also have
important implications for the future of mycobacterial disease. Using
admission data stratified by year for pulmonary NTM and pulmonary TB
during the study period, an inverse relationship can be observed between
the two causes of pulmonary mycobacterial disease. TB incidence as
represented by national hospital rates is on the decline during the study
period while hospitalization due to NTM is rising. See the figure below for
a visual representation of the epidemiology of pulmonary NTM and
pulmonary TB.
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Figure 7: Epidemiological data for hospitalizations due to mycobacterial
diseases in the US
Clinical Findings
Finally, clinical outcome measures were recorded as a means of
understanding the impact of mycobacterial diseases relative to morbidity
and mortality. A number of clinical measures were included. First,
hospital length of stay was recorded for both pulmonary NTM and
pulmonary TB. One interesting finding of this study was that TB patients
had a longer hospital stay compared to NTM patients, TB averaging 13
days versus 9 days for NTM but the mean hospital charge per admission
was only marginally higher for TB as compared to NTM. This finding
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implies an average per diem hospital charge for NTM of $5,121.74 versus
$3,580.15 for TB. Another important outcome measure is mortality.
Mortality was recorded for all hospital admissions in which the patient died
during the hospital course. The average death rate for NTM appears less
in numbers than TB, but represents a higher percentage of patients. This
result is reflected by the lower number of NTM infections, but
demonstrates a higher likelihood of mortality. See the table below for
discharge data and clinical measures for NTM and TB.
Table 21: Clinical outcomes of patients with pulmonary NTM and TB

Variables	
  
Pulmonary mycobacterial infection
admissions	
  
Length of stay in days 	
  
Average in-hospital mortality
(mean/year)(percentage)	
  
Mean hospital charge per admission ($)

NTM 	
  

TB 	
  

20,049	
  

44,370	
  

9.2	
  

13.5	
  

71 (35%)	
  

114 (26%)	
  

47,120

48,332

Study Strengths
This was a population-based study that focused on the cost burden
of inpatient care of patients with pulmonary mycobacterial diseases in the
US between the years 2001 through 2012. Overall cost was determined
to be around $3 billion during the study period. The aggregated hospital
charges for pulmonary NTM had an increasing trend that was in the same
trajectory with the health care inflation. However, pulmonary TB inpatient
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costs were not increasing at the same rate as the trajectory of health care
cost inflation. One could argue that the cost of managing TB during the
study period was effectively decreasing.
In addition to the measurement of cost, this study also identified
important demographic features of both diseases. Compared to patients
with pulmonary TB, patients with pulmonary NTM were more often
women. The relationship between women and NTM is well described.
Also, NTM patients were older and came from areas with higher incomes,
which has been found in other studies. In a 2014 review, Mirsaeidi and
colleagues profiled a 70-year-old white female patient with pulmonary
NTM as a typical case of NTM facilitating a discussion of NTM and
females and the elderly. The authors explained that the elderly are at an
increased susceptibility to NTM pathogens and noted the unique treatment
challenges due to health status and comorbidities.323 Another review
noted the strong association between NTM and the elderly,
immunosuppressed patients of all ages, HIV/AIDS, and the availability of
solid organ transplantation as an option for treating a myriad of diseases.
The authors of this review note that NTM rates continue to rise, which is
likely related to both population features as well as advances in detection
methods. However, standards have yet to be established in management
and treatment for most patients. Better evidence based recommendations
based on the availability of well-designed clinical trials is critical to the
future management of the disease.324 A comparison study conducted in
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Australia compared NTM isolates obtained in 1999 and 2005 along with
clinical features. This study found that NTM incidence increased from 2.2
per 100,000 in 1999 to 3.2 per 100,000 in 2005. This study also noted
important demographic changes in the disease during the study period. In
1999, NTM was more common in middle-aged men who smoke while
2005 identified the most common demographic were elderly women.325
These findings are important for several reasons. First, a recent
population-based study demonstrated that females die more frequently
from NTM and the majority (78%) of NTM-related mortality occurs in the
patients 55 years of age or older.326 The association between elderly
females and mortality were also confirmed in a study presented at the
2016 IDSA meeting.327 Other demographic characteristics are also well
described. In a sample collected from Medicare Part B of patients with
pulmonary NTM between the years 1997 and 2007, Adjemian and
colleagues showed a relationship between the prevalence of disease in
counties in the US with a higher median household income. This study
also identified the geographical distribution of disease using cluster
analysis, noting that counties in warm areas like Louisiana, Florida and
Hawaii were at a higher risk for pulmonary NTM as compared to counties
in Rhode Island, Michigan, Minnesota and West Virginia.328 The findings
in this study were consistent with those available in the peer-reviewed
literature.
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Study Limitations
This study measured hospital charges associated with pulmonary
mycobacterial diseases in the US. It is important to note that healthcare
costs as represented by collections were estimated based on average
collection rates per payer as actual collection rates are not available
because this data is considered proprietary contractual information. In
addition to direct medical costs having been estimated, this study failed to
capture a complete picture of economic impact as most every cost study
does. The full economic burden of mycobacterial disease, as is the case
in almost every chronic disease, is very difficult, if not impossible, to
measure. In addition to the cost of delivering direct medical care in the
inpatient and outpatient setting, total cost involves many other financial
and human costs. These costs may include lost wages, travel expenses
and opportunity costs of the sick, the cost to administer public health
programs including surveillance and prevention, and the economic impact
on the family and social network of those receiving care for the disease. It
is important to note that the measure of total economic cost for any
disease is outside of the scope of most studies.
Another major limitation of the study was the use of ICD-9 billing
codes as the search term for the database. ICD-9 coding in this study has
several important limitations. First, while more than150 species of NTM
have been identified as causes of disease in humans, ICD-9 billing only
itemizes M. avium, M. interacellulare and M. kansasii. Although these
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species represent the most common cause of disease in humans in North
America, an international average has recorded these species as a cause
of human disease in only half of cases worldwide.329 Therefore, it is safe
to assume that this study failed to capture a significant portion of NTM
cases caused by other species, which leaves many unanswered questions
regarding the true cost of care for patients hospitalized with NTM disease.
Another important limitation associated with ICD-9 is that this study
population only includes patients hospitalized with pulmonary
mycobacterial disease. TB and NTM can cause disease processes in
most every part of the body including but not limited to skin and soft
tissue, bone and joint, other major organs and disseminated disease.
Although these cases are less common than pulmonary disease, they are
more common particularly in immunosuppressed hosts and represent an
important cost driver in the management of mycobacterial disease.
This study was limited to inpatient cases of NTM and TB.
Mycobacterial diseases are frequently managed in an outpatient setting
given the chronicity and sometimes mild symptoms, so these cases of
pulmonary NTM and TB were not considered in this analysis. Further, it is
not uncommon for NTM to be diagnosed in hospitalized patients following
discharge given the slow growth of the pathogen in the laboratory.
Therefore, patients with pulmonary NTM are assigned another billing code
in these cases such as community acquired pneumonia, and were not
included in this study. In the event of a readmission, cases would be
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coded correctly and only for subsequent admissions. Therefore, all cases
of pulmonary NTM due to M. avium, M. interacellulare and M. kansasii
were not included in this study. Given these important limitations, it is
important to emphasize the cost of managing TB and especially NTM
most likely significantly exceeds what was measured in this study.
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CHAPTER 4: DISCUSSION
The purpose of this study was to determine the cost of care of
managing two important diseases in the US. Although the cost of TB has
been extensively measured in a variety of care settings, this study offered
another perspective of TB management cost in the US as well as
identified important cost and epidemiological trends. Also, this study
contributed to the emerging cost data for the more elusive group of
pathogens known as NTM. Additionally, epidemiological and cost trends
are identified in this study showing an increase in both. This study offers
important information establishing the importance of NTM for future
research. Further, the findings of this study have several important
implications for public health policy.

Implications for Policy
Globalization is a contemporary construct that describes the free
movement of people, information, goods and services accessed across
political and physical borders that separate countries, continents, cultures,
religions, and societies. Borders in the modern world are fluid as
populations shift, information is shared, and economies are intertwined.
Globalization also has important implications for health as global
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connectedness is demonstrated by the exposure of disease by the
interaction of populations with one another and a common environment
like never before, leading the epidemiology of many diseases to be
transformed into global public health challenges.
Policy makers who design and evaluate local and national health
policy face many challenges due to the complexities and dynamics of
influence from the outside. A number of tools and frameworks are
available to these experts that reduce the factors influencing a system and
its drivers in order to identify opportunities to intervene and influence
drivers that impact outcomes as a means of reaching program goals.
Among these frameworks is the Ladder of Engagement, which offers an
important decision support tool allowing policy makers to reduce complex
systems to linear terms. The Ladder of Engagement utilizes both Systems
Thinking and Dynamic Modeling by identifying catalysts that drive human
behavior over time. Through the identification of nonlinear relationships
represented by both positive and negative feedback loops, policy makers
are able to isolate indicators of system behavior that represent
opportunities for policy interventions that would enhance the ability of
public health programs to be designed to reach policy goals.
System Dynamics: Systems Thinking and Dynamic Modeling
Critical to the process of System Dynamics is the use of two equally
critical and consecutive steps: Systems Thinking and Dynamic Modeling.
Systems Thinking provides the conceptual framework for establishing the
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elements used in Dynamic Modeling, ensuring that the model is
representative of the system so that accurate and reliable simulations
occur.330 Systems Thinking alone provides an incomplete analysis of the
process because the complexity of mental models exceeds one’s capacity
to fully understand the implications without the process of model creation,
mapping and simulation. Just as Systems Thinking is dependent on
Dynamic Modeling for providing advanced simulations and experiments
predicting interactions and behaviors in a system, Dynamic Modeling is
equally dependent on Systems Thinking to establish the model
conceptually and represent the relationships and interactions accurately
so that simulations and experiments precisely reflect the dynamics of the
system.331
Systems Thinking represents the first step in the process in which
policy makers become oriented with the situation and capture the
connection between parts and understanding their relationships to the
functioning whole. Although this step is considered qualitative, it does not
represent a rejection of traditional scientific views built on mechanic and
linear relationships. Instead, Systems Thinking builds on these concepts
with increased complexity rather than undermining them while requiring
one to conceptualize systems as wholes as well as to precisely identify
critical relationships and interactions that impact the whole.332
Dynamic Modeling refers to the quantitative aspect of the System
Dynamics that involves the use of models and simulations to increase the
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understanding of policy makers of complex systems. The opportunities for
policy makers to use Dynamic Modeling to approach complex problems
are significant as modeling represents a method of understanding change
in a complex and dynamic system so that the influences within can be
better understood and the direction of the system can be governed. Also,
mapping and simulation allows policy makers to identify potential
opportunities within the system for the most effective policy interventions
to optimally navigate system change.333 These experiments allow policy
makers to input different policy interventions and better visualize
outcomes relative to policy goals and those unrelated including
unintended consequence as a means of evaluating policy prior to
implementation. Although the purpose of constructing these models is not
to necessarily to allow policy makers to make predictions into the future,
modeling does have the potential to shed insight into how behavior and
interactions over time will impact the system.334
The Ladder of Engagement
System dynamicists possess a myriad of backgrounds and
expertise as notable in the Center for Interdisciplinary Excellence in
System Dynamics. This diversity in background has led to the
development of a collaborative model for approaching complex problem
solving. The Ladder of Engagement was developed and refined as a
means of progressively and comprehensively understanding and
describing complex interactions and behaviors in a system. The model
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consists of three separate but dependent levels: knowledge,
understanding, and influence.
Knowledge
Critical in the knowledge segment of the Ladder of Engagement
framework is knowing how a system behaves. Therefore, defining the
problem and developing an accurate and representative problem
statement is the first step in the process. This step is critical in identifying
contributing factors to a problem situation and conceptualizing the
relationship. Also, the mapping process key in Dynamic Modeling is
initiated as positions within the system, or stocks, are identified and
defined relative to outcome stocks. When mapping global public health
problems, the most critical stocks in a system is death, and the positions
within the system that flow directly into death may represent the problem
situation.
Understanding
The next step in the Ladder of Engagement Framework is understanding.
This step involves the identification and evaluation of leverage points in
the system that can potentially drive behavior. This too calls for
conceptualizing relationships as part of the Systems Thinking process as
well as building on the established model. During this step, positions
within the system are identified and represented by their role in affecting
behaviors and outcomes within the system over time. These positions are
represented in the model as stocks. Stocks that have an influence on a
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desired outcome may identify opportunities in which this influence can be
magnified. Stocks that have an undesired outcome are identified as
leverage points. Opportunities to reduce the flow into an outcome stock of
death exist in these positions.
Influence
This is the final step in the analysis in which policy makers
determine whether the identified opportunities in the system are modifiable
through policy change. A systems dynamicist would likely employ the
simulation phase of the Systems Dynamics process after policy
development but prior to implementation to determine whether policy
outcomes met policy goals and to identify resulting unintended
consequences using the stock and flow modeling process.335
Systems Dynamics and Public Health
Systems Dynamics has been used to address public health issues
since the 1970s. Among these issues include disease epidemiology for
both chronic diseases and infectious diseases, substance abuse including
tobacco as well as illicit drugs, the movement of patients through the
healthcare system including from emergency care to long term care
facilities, healthcare resource capacity and delivery as conducted by
HMOs, and the interactions between healthcare capacity and public health
capacity in relation to specific disease epidemiology.336 The identification
of public health issues appropriate for Systems Dynamics tools are
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relatively easy to identify and, often times, the catalysts are likewise easy
to isolate.337
Systems Dynamics tools are being used in the surveillance of
diseases in order to identify emerging pandemics and form response
strategies. The Centers for Disease Control and Prevention (CDC)
possesses a well-established role in disease surveillance. Using their
proprietary system called BioSense, the CDC is able to feed
epidemiological data into the system from local, national and even
international sources to identify emerging and predict existing outbreaks of
influenza. This software allows the CDC to identify outbreaks sooner, in
which case the organization is able inform and mobilize local health
departments as well as policy makers so that the appropriate action can
be taken to prevent further disease spread. In this example, the CDC
identified a potential influenza pandemic as a problem situation due to the
1918 outbreak of the Spanish flu as well as the anticipated avian flu
pandemic. Mapping the problem and understanding epidemiological
outbreak patterns associated with influenza led to the development of this
simulation software to deliver predictions in real time. Another example is
the Laboratory Response Network, also managed by the CDC, which
relies on an integrated system of laboratories that collect and feed data
regarding communicable diseases and bioterrorism into a simulation
program to allow for the rapid identification of a disease outbreak or acts
of bioterrorism. Additionally, the software provides decision support in the
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formation of a response plan.338
Despite the potential utility of Systems Dynamics to public health,
many public health interventions in the US fall short of policy goals due to
the inability of policy makers to approach problem situations holistically.
The reason for this lies in the fragmented organizational and funding
structure of public health. As a result of these institutional barriers, public
health is unable to assess and implement policy that addresses system
wide catalysts. Instead, policy is enacted in increments over time and
often lacks the foresight and scope to address future complex problems.
Therefore, public health is particularly in need of complex analytical tools
to accurately and comprehensively address population level needs in the
present and anticipate future needs by identifying and understanding
trends over time. Public health has seemingly settled for an incomplete
analysis including only the conceptualization of complex problems, and
this approach has proven incomplete with the absence of simulation
studies.339 Although Systems Dynamics is particularly well suited for
public health programs and interventions, institutional constraints in the
US have acted as hindrances to the ability of state and local public health
departments to explore System Dynamics tools in complex problem
solving.
Mycobacterium Tuberculosis
Public health policy for Mycobacterium tuberculosis (TB) in the US
has focused on prevention through screening, contact tracing and early
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treatment. Despite institutional challenges, TB policy in the US has been
very successful in preventing the transmission of disease within local
populations. These results have been shared in other industrialized
nations. Also, this preventative approach utilized in North America and
Western Europe has been validated by systems dynamic modeling. In a
2011 Canadian study, a dynamic model was used to evaluate contact
tracing and its role in the prevention of TB transmission. In this model, the
population was categorized based on risk status and health status and
placed into one of ten stocks. However, individuals who had been
identified as an at risk contact under investigations through contact tracing
were placed in the eleventh stock due to possible disease exposure. The
model illustrates transitions between stocks flowing in the upper part of the
diagram downward to demonstrate the change in status relative to risk of
infection over time. Tian and researchers ran the model in this study, and
their data supported the role of contact tracing in a theoretical closed
community. However, the findings of this study implied the expansion of
the program currently being used in Canada could yield diminishing
returns. See the figure below for a visual representation of the model
used in this study.340
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Figure 8: TB contact tracing model
Despite the successes of TB control in many countries, TB remains
an important cause of disease in select populations worldwide. Among
the consistent features of TB is its association with poverty. Whether this
relationship is observed in overall wealthy societies in which poor
populations are disproportionately affected or poor countries in which the
average population of impoverished citizens is affected, where one finds
poverty is likewise where one finds TB. The financial and economic
burden in a variety of these settings has been well described in the
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literature. However, policy challenges are looming in some care settings
while others have had considerable success.
In the developing world, a significant amount of research has been
conducted on the economic burden and overall ramifications of disease to
countries and its citizens in these care settings. According to a systematic
review, the average cost burden for those accessing TB treatment found
across studies was as follows: 20% direct medical care, 20% indirect
medical care, and 60% lost wages. The WHO argues that programs
designed to meet the needs of patients should address economic costs
including the provision of direct costs, indirect costs, as well as lost wages
of those with disease and their families and caretakers.341,342 Policy
research agrees that without full economic support, TB patients may not
be able to access TB treatment resources or complete treatment
regimens.343 The impact of not ensuring patients have the resources and
support to have access and be compliant with treatment on a global scale
is arguably more significant than its cost. The identification of TB in
populations coupled with appropriate treatment hurdles cost exponentially
by preventing further transmission and undermining the facilitation of drug
resistance.
Systems dynamics can be applied to TB to this scenario using the
Ladders of Engagement method. In the underdeveloped world, two major
undesirable outcomes exist. The first is death, and TB as a cause of
death is an important medical problem in most every country. The other
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undesirable outcome is drug resistant TB, which occurs through
transmission from one person to another or occurs following inappropriate
treatment.344 This initial model represents knowledge of the situation.
Stocks that feed into these outcomes are treated and untreated TB, which
represent an important opportunity for intervention according to most
studies. Assuring that diagnosed patients receive treatment is critical to
TB control in most resource scarce high burden countries. Not to say that
the stock of patients who adhere to TB treatment do not have poor
outcomes, but the stock that does not receive and complete treatment
runs the highest risk for death as well as developing drug resistant
disease. This represents the second step, which establishes an
understanding of the situation. Barriers to treatment are mostly cost, and
it is important to note that this population is usually unable to absorb any
costs including direct medical care, indirect as well as lost wages without
extreme hardship. According to the literature, the total average patient
costs in all care settings was equivalent to approximately one year of
individual income.345 Therefore, the ability to access treatment represents
the most critical barrier for this population and characterizes the most
important opportunity for policy intervention. Identifying opportunities as
well as evaluating policy proposals prior to implementation occurs during
this step. It is also important to note that policy makers should fully
understand the impact of policy relative to unmet needs and policy goals,
in addition to the identification of unintended policy outcomes that may
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influence the quality of the intervention.
TB control efforts by public health have been successful in the
developed world including the US. However, these measures have only
been effective in local populations as 64.6% of TB cases occurred in
populations born outside the US.346 In the US, death secondary to TB is
not as common as compared to outcomes in developing countries but TB
policy has a much stronger emphasis on prevention. Therefore,
undesirable outcomes for policy makers include the disproportionate rate
of infection in immigrant populations primarily from high TB burden
countries. The major contributing factor in the US is immigration policy
itself, which also represents an important opportunity for policy
intervention given that the target group can be screened for active and
latent disease during the immigrations process. According to policy
researchers, universal screening for active disease using chest
radiography has been widely disproven due to high cost and low yield.347
Therefore, targeted screening has been proposed that limits the time and
expense of chest radiography to migrants from high burden TB countries
following face to face interviews in which risk profiles and clinical
information are correlated.348 In this case, the stock of TB would be
decreased with targeted screening more effectively and a lower cost than
universal screening. However, using the immigration process as a segue
to TB control in select migrant populations limits the reach of TB control to
legal migrants.349 Outreach to TB control in illegal immigrant populations
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could be accomplished through one of several methods. First, a reduction
in illegal immigration through increased border control could effectively
reduce the number of new cases of TB in the US. Another option is to
amend immigration policy so that immigrants may enter the US legally and
therefore be subject to the same processes as other migrants. Both of
these interventions would require widespread political support coupled
with action from legislatures, which is unlikely given the controversial
nature of immigration policy in the US. Another option is to design an
outreach program managed by public health specifically to reach illegal
immigrant populations. For this program to be successful, public health
would be responsible for the identification of and significant relationship
and trust building with invisible populations of illegal immigrants who often
wish to remain invisible due to fear of discovery and deportation. For
illegal immigrants, the stock of TB would be decreased by public health
outreach to these populations. Policy research generally agrees that to
tackle the issue of TB in foreign-born populations, a complex multi-system
approach is necessary to targets at risk populations through various
approaches.
Nontuberculous Mycobacterium
Having only been discovered in 1959, NTM is an emerging public
health problem for which local and global policy has not been
established.350 Despite this, NTM is an increasingly important cause of
morbidity and mortality in the US and possibly the world.351 In fact,
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evidence suggests that NTM is a more common cause of death in the US
than TB.352 Key features of the disease make the formation of policy
particularly challenging. First, clinical signs and symptoms result in the
disease being easily confused with TB in many health care settings,353 but
epidemiology and modes of transmission are absolutely different.
Therefore, effective policy that addresses NTM infection must be unique
and not simply a modification of effective TB surveillance and control.
In the developing world, NTM has been barely described.
Therefore, the epidemiology of NTM disease in resource constrained care
settings has not been published. Some data indicate that NTM infection
may be incorrectly labeled in many care settings in the developing world
as drug resistant TB infection. TB drugs being used incorrectly to treat
NTM infection represents inappropriate antibiotic use and has important
long-term consequences for the future of antibiotic effectiveness and
short-term costs.354,355 It is also possible that in some cases, people in the
developing world are co-infected with both diseases. In these cases,
initiating TB treatment only partially treats one infection leading clinicians
to consider these patients a treatment failure and continue anti-TB drugs,
or modify to second tier for supposed drug resistant TB. Both of these
scenarios also represent inappropriate antibiotic use as well as over
utilizing healthcare resources. It is also important to note that in the
developing world, the epidemiological differences of affected populations
and the geographical distribution of disease has not been established.
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Therefore, these factors cannot be used for diagnostic support in the
developing world. Only through the use of laboratory techniques can NTM
in this care setting be accurately diagnosed.
The undesired outcomes for NTM are undiagnosed and
misdiagnosed NTM disease. When patients are being evaluated for TB, it
is at this point that policy makers would suggest an intervention in which
patients are diagnosed using laboratory methods that can accurately
differentiate between different species of mycobacterium disease
assuming access. This is particularly challenging in some parts of the
world in which laboratory methods are antiquated, infrastructure is subject
to supply shortages including water and electricity, or TB is diagnosed
without the use of laboratory methods in particularly resource constrained
care settings.356 In these cases, the introduction of enhanced laboratory
methods to identify cases of NTM infection might represent the
establishment of new infrastructure, which may not be possible. However,
in countries with a high burden of drug resistance and HIV/AIDS, data
establishing that these cases sometimes are misdiagnosed NTM could
stimulate the demand for mycobacterium species typing if a significant
portion of the TB control budget is being used for the treatment of drug
resistant cases. Therefore, policy makers must rely on more research in
the epidemiology of NTM disease in developing countries before having
the ability to measure the impact of policy interventions.
NTM in the developed world is slightly more described. First,
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infection rates have been on a steady incline as demonstrated by reports
in the peer reviewed medical research as well as this population-based
study.357 Also, given its association with the elderly and immunesuppressed hosts, the differing epidemiology in some cases allows the
clinician to better identify NTM infection amidst TB infection.358,359,360 Also,
accurate microbiological detection methods have been able to tease out
NTM cases with the appearance of TB with remarkable accuracy.
Currently, it remains unclear whether NTM rates are truly rising or the
identification of NTM species coupled with the improvement of detection
rates have resulted in the incline during the study period.
Despite these questions, many researchers in the peer-reviewed
literature believe NTM rates truly are increasing. Among the explanations
are population features in the US and much of the developed world that
are uniquely different from those in the developing world. First, the
distribution of age in the US as well as many western European countries
has resulted in a large segment of the population being considered
elderly.361,362 As discussed, older age is an important risk factor for NTM
infection. Another important risk factor for NTM infection is suppressed
immune status, which may result from a number of causes in the US
including HIV infection, post-transplant therapy, immune modulating
therapy, and cancer treatment. This is also increasingly common in the
US and is likely to also contribute to the incidence of
disease.363,364,365,366,367,368 Another theory is the infrastructure of the built
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environment. NTM is primarily transmitted from environmental sources
including soil and water.369 Several studies have sought to identify
specific modes of transmission in patients with confirmed NTM infection by
confirming the presence of the same NTM species in water samples
collected from their homes. Researchers have demonstrated the pathway
to transmission from water sources through the aerosolization of water
from showerheads and hot tubs. NTM has also been identified in public
water sources.370,371 Further, some researchers have suggested that NTM
is a result of the progress of modern societies as the disease is
transmitted through the public water distribution infrastructure.372 Another
possible pathway for NTM infection is in the food supply.373
In the US, the undesired outcome for policymakers is NTM
infection. As public health is well acquainted with employing measures to
prevent the person-to-person transmission of diseases, measures to
prevent disease transmission from the environment is largely uncharted
territory. Although the removal of NTM species from surrounding nature
sources is not possible, preventing the transmission of disease from public
water and food might be an opportunity for a policy intervention.

Policy Recommendations
The purpose of this study was to better understand the emerging
public health challenge of pulmonary NTM infection as presented in the
context of the well-established public health challenge of the genetically
similar pulmonary TB disease. Using data methodology to compare the
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cost of care and epidemiology of both diseases as well identify trends over
time, this study confirmed the importance of pulmonary NTM as an
increasingly critical public health challenge. This designation leaves
important questions for the future of this disease as well as the implication
of public health policy intervention and further research.
System dynamics can be an important decision support tool for the
formation and evaluation of policy for select problem situations. Ideally,
the problem situation should be clearly definable given that the
relationships and catalysts have been studied and identified and the
dynamic behaviors that feed the causes and effects of these relationships
are well understood. Because transmission patterns for NTM disease
remain elusive in the current body of medical research along with the
incidence of disease in select population with identifiable risk factors
seeming to occur sporadically, the cause and effect of this problem
situation remain obscure. This leaves many challenges for the formation
of an effective intervention using this particular decision support tool.
Therefore, much more needs to be learned about NTM from both a
scientific and policy perspective in order to craft effective interventions that
undermine the incidence of disease in populations in the US and
worldwide.
Although systems dynamics may not be suitable for the evaluation
of pulmonary NTM policy given that currently available data are limited,
the mapping of not well understood problem situations can reveal
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important implications for future research and the early formation of
holistic policy. Mapping may lay the foundations for defining important
relationships leading to discoveries being made regarding the cause and
effect of important interactions. Also, opportunities for policy interventions
may be revealed during this process, although in the absence of dynamic
modeling they may not be testable. In select situations in which policy
interventions may be suitable despite the absence of ideal confirmatory
data to support its efficacy, mapping alone may be an important step in
the process of forming preliminary but effective policy. Mapping may also
identify what necessary data is needed to better understand a policy
situation, which may be an important precursor to policy formation.
The mapping of NTM as an emerging public health problem in the
US reveals important opportunities for policy makers. First and foremost,
mapping demonstrates that not enough information is known about two
very important aspects of NTM disease. The first is epidemiology. The
distribution of NTM disease remaining unmeasured is a global problem,
with the few data that exist having been pieced together from various
studies that still only represents an unknown fraction of NTM cases. The
mapping of NTM along with current research also reveals that little is
known about clinical aspects of NTM disease. Considering that modes of
exposure, transmission, and risk factors remain under described by
current medical knowledge, the use of these variables in a model map
only reveals to system dynamicists the information that remains
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outstanding before proceeding to the next step. In this case,
understanding variables may represent key opportunities for policy and
research. See the figure below for a comprehensive map that represents
the known relationship between NTM with risk groups and the
environment.

Figure 8: Mapping of NTM Transmission and Illness
Given that so little is known about the epidemiology of NTM
disease, the first important policy recommendation might be in the area of
disease surveillance. This might be achieved through the public health
designation of NTM as a reportable disease. Public health classifies
select diseases as reportable that have been designated as particularly
important public health problems. In the US, diseases are reported to
public health agencies in a variety of ways. For some diseases it is
mandatory for each case to be submitted by paper reports or by telephone
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or even by computer, depending on the disease. Gonorrhea is an
example of a disease that is reported using paper forms whereas
pertussis is reportable by phone. In these cases, identifiable data are
often collected in order to allow contact investigation. Other diseases are
reported to public health by proving a count of diagnosed cases. Influenza
is an example of a disease in which merely the number of cases
diagnosed is reportable.374 All surveillance data are reported to the
National Notifiable Diseases Surveillance System (NNDSS), which houses
local, state, and national data managed by the CDC Division of Health
Informatics and Surveillance (DHIS). The DHIS submit, process and
release data from the NNDSS to all levels of public health to support
surveillance and analysis of disease distribution on all levels of
government.375 The purpose of disease reporting to public health
agencies is to provide local, state and national surveillance of important
diseases in order to identify early trends in the occurrence of disease.
The ultimate goal is to maintain a constant measure of disease distribution
to gain a better understanding of baseline disease occurrence, prevent
outbreaks as well as to undermine the natural trajectory of future cases.376
The accuracy of national surveillance data for reportable diseases
has been questioned. In a 2011 study conducted in North Carolina,
researchers found that complete reporting rates varied among the eight
health care systems studied from 2% to 30%. Also, of the fifty-three
diseases evaluated, reporting completeness rates ranged from 0% to
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82%. The discrepancy in reporting did not seem to be related to the
perceived public health importance of the disease in question. Instead,
diseases that were diagnosed through straight forward laboratory methods
or clear clinical criteria were more likely to be reported than those that
were difficult to identify clinically and/or involved multiple laboratory steps
to establish a diagnosis.377 Also, physician knowledge regarding
reportable diseases has likewise been questioned. A survey study of 162
emergency department physicians representing 34 states in the US
indicated familiarity with IDSA guidelines for infectious foodborne
pathogens, but did not demonstrate the same knowledge regarding the
public health importance and reporting requirements. Given that
emergency departments represent primary care form so many Americans,
this finding is of increased importance.378
Recent federal legislation encouraging the use of information
technology in healthcare has also sought to improve the rates at which
notifiable diseases are reported. The American Recovery and
Reinvestment Act of 2009 in combination with the Health Information
Technology for Economic and Clinical Health (HITECH) Act has
encouraged widespread adoption of electronic health records by providing
federal incentive funds to providers who adopt and maintain its use.
Among the components of health record technology qualifying for
incentive is the inclusion of disease surveillance and electronic reporting,
which is expected to not only increase the rates of reporting, but also
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reduce the number of errors and incomplete reports submitted with public
health departments and the CDC.379 380 In a comparison study evaluating
traditional reporting methods to the local health department with
automated electronic laboratory reporting through a health information
exchange, a total of 4785 reports for 53 reportable conditions were
evaluated. This study found that automatic electronic laboratory reporting
identified 4.4 times as many cases as traditional reporting and did so on
an average of 7.9 days sooner.381 Given the widespread adoption of
electronic medical records secondary to HITECH, it is conceivable that
automatic improvements in the availability of surveillance data for
reportable many diseases may be an important policy outcome. However,
the WHO notes that the reporting of some notifiable diseases on an
international level do not occur for a variety of reasons US. First, some
cases of disease may not be treated in a healthcare setting, but instead at
home, in which case there would be no official record. Also, reportable
disease may not be diagnosed properly, which would undermine reporting.
In these cases, the disease in question may be difficult to diagnose or the
healthcare facility may not have adequate resources to make an accurate
laboratory based diagnosis. Also, reporting of notifiable diseases may be
less common in under resourced healthcare settings despite the ability to
make accurate diagnoses if employees are not educated or motivated to
comply with reporting. Finally, a fear of economic or political
consequences may result in some diseases being intentionally not
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reported.382
NTM as a reportable disease would have several distinct
challenges. First, NTM is commonly confused with TB as they often
present with similar clinical symptoms. Also, NTM is diagnosed through a
multi-step, slow laboratory process, which current research has shown
would reduce the frequency of reporting. Further, it is not uncommon for
NTM to be diagnosed following hospital discharge, resulting in patients
being managed for community-acquired pneumonia. In these cases, is in
uncertain how disease reporting would proceed as medical coding is
rarely updated. For these reasons, it is likely that designating NTM a
reportable disease will still not provide a complete picture as is the case
with many reportable diseases, but the designation of NTM as a
reportable disease would vastly improve current available data on the
disease.
Another method of improving surveillance data for NTM disease
involves piecing together currently available data sources. Using national
hospital data, as was the case in this study, provides one aspect of NTM
epidemiology as well as the cost of care. Combining these results with
outpatient data that are available in the form of searchable datasets using
ICD billing codes for each payer including commercial insurers and public
payers could provide a more accurate epidemiological picture. However,
the collection of outpatient data would represent a laborious process to
collect and analyze each individual dataset. Given that research in the
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field of NTM is likewise not being highly encouraged by the availability of
abundant funding or significant scientific interest, the availability of said
data that is matched with that of this study is not likely to be published.
Further, the limitations of these data would be the same for this study,
primarily the use of ICD-9 codes in which only three species of NTM was
captured. Finally, piecing hospital data with outpatient billing with
searchable billing codes would offer a much closer-to-complete picture of
NTM especially if ICD billing codes were to include more species of NTM,
including a designation for other common atypical mycobacterium species.
The table below outlines the current billing codes allotted for NTM
infection.
Table 22: ICD-10 Billing Codes for NTM Infection

Atypical Mycobacteria
A31.0

Pulmonary mycobacterial infection

A31.1

Cutaneous mycobacterial infection

A31.2

Disseminated MAC

A31.8

Other mycobacterial infections

A31.9

Mycobacterial infection, unspecified
Since the ICD-10 update, pulmonary NTM remains only applicable

to infections caused by M. avium, M. intracellulare, and M. kansasii. Other
NTM infections specified by current billing codes include cutaneous NTM,
which refers to necrotizing skin and soft tissue infections caused by NTM
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organisms M. marinum and M. ulcerans. Also, disseminated disease
caused by MAC is itemized alone. Other mycobacterial infections are
specified to include disseminated NTM caused by M. abscessus, M.
chelonae, M. chelonei, M. fortuitum, and M. gordonae. The final code
designation applies to any other disease process caused by NTM and/or
any other species of NTM.383 Although this represents an expansion of
ICD-9, given the sheer numbers of NTM organisms as well as the
potential for involvement of virtually any part of the body, relying on billing
codes to define the presentation and distribution of NTM disease in the US
might not be realistic.
Another important policy implication is, therefore, that research and
scholarship in the area of NTM should be encouraged through the
availability of national grants to facilitate a better understanding of this
increasingly important cause of morbidity and mortality in the US. Given
that NTM is estimated to be a more important disease in the US than TB
by several measures, it is questionable that more data continues to be
generated in the various aspects of TB infection. A study published by
Raju and colleagues explains that as long as the NIH continues to largely
ignore NTM as an important cause of human infection by supporting very
few funded studies, NTM as an important cause of disease will continue to
be under appreciated.384 Further, private sector interest in the treatment
of most infectious diseases has been low for some time, given that
research into chronic conditions for which long-term maintenance

152

medications are often prescribed represents a stronger revenue model for
private sector research. One important exception is HIV/AIDS, due to the
chronicity of infection that results in lifetime treatment regimens for most
patients. Further, political support for research in the area of HIV/AIDS
coupled with the willingness of the Food and Drug Administration to fast
track new therapies has also stimulated private sector interest. It is
unlikely that NTM could rally similar support, but any discussion on the
importance of NTM disease in the private sector could have an impact.
Further, the single act of designating NTM as a reportable disease could
facilitate both public and private sector interest, especially following the
availability of more accurate surveillance data.
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CHAPTER 5: CONCLUSION
Mycobacterial diseases are a global health problem, representing a
source of an immeasurable and significant economic burden. Describing
infections caused by Mycobacterium tuberculosis (TB) and
Nontuberculous mycobacteria (NTM), mycobacterial diseases represent
important public health problems with significant health and economic
consequences. Both TB and NTM have many clinical presentations, but
the most common manifestation of disease is pulmonary. Also, both TB
and NTM have a similar clinical picture along with characteristic nodules
observable on lung imaging for pulmonary disease that is very distinct
from other infectious diseases. Despite similarities, TB and NTM differ
dramatically in a number of ways. In developing countries, NTM is more
strongly associated with older hosts, particularly women, and those with
underlying diseases that affect lung structure, undermine immunity, or
those with medical conditions that require immune modulating therapies.
TB, however, is associated with younger men, while comorbid conditions
and unhealthy behaviors may also represent important risk factors. TB is
also strongly associated with vulnerable populations including recent
immigrants from high burden TB countries. In the developing world, the
different demographic features of the two diseases are less described.
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Given that emerging research indicates that the two diseases are often
confused due to the similarities in clinical appearance coupled with a lack
of available diagnostic tools that accurately differentiate between the two
diseases, it is understandable that in some care settings how little is
known about NTM relative to TB. However, the misdiagnosis of
subsequent inappropriate treatment of NTM as TB or drug resistant TB
has important worldwide implications for both cost of care as well as
clinical outcomes. Also, inappropriate treatment has important
consequences for the future treatment of mycobacterial diseases by
facilitating drug resistance.
One important similarity between the two diseases in most every
care setting is the economic consequences of infection. Mycobacterial
diseases caused by both TB and NTM represent serious infections that
require months of treatment along with routine monitoring to ensure
clinical response to treatment. Also, the risk of side effects due to
extended antibiotic therapy is high and must be monitored along with
treatment progress. For patients and their families, the cost of medical
care coupled with the economic cost of lost wages, travel and other
expenses can be devastating for many in developing countries as well as
for vulnerable populations living in poverty in developed countries. Given
that mycobacterial diseases have a strong association with poverty, the
impact of disease on people and local economies can be catastrophic.
Further, in some societies a diagnosis of mycobacterial infection can also
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have personal consequences considering the stigma of disease. This is
particularly the case with TB infection as people have reported
discrimination for employment, mate selection, and isolation from family
and other important social networks.
In the US, mycobacterial diseases represent a unique challenge.
TB in the US has been successfully controlled following effective
population based public health policy interventions focused on early
identification and preventions. Despite major challenges in TB care,
including drug resistance and co-infection with HIV disease, rates have
been stable and even decreasing in recent years in the US. In local
populations, the success of TB control can be better measured as rates
have declined drastically. In recent immigrant populations, the distribution
of TB infection is disproportionately high, especially in immigrants from
high burden TB countries. Policy makers have suggested a number of
programs focusing on immigrant populations as part of a multi-level
approach to identify latent disease, active disease, and reaching both
documented and undocumented immigrant populations. NTM, however,
represents an emerging public health problem with death rates on the
sharp incline in the US. Given that NTM tends to be associated with older
populations with comorbid conditions commonly associated with aging, the
current population structure in the US will likely continue to explain future
increases in NTM incidence. The cost of care for both diseases is likely to
reflect these challenges.
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According to this study, the cost of care of managing mycobacterial
diseases in the US between the years 2001 and 20012 was around $3
billion. During the study period, the aggregated hospital cost increased for
both diseases. For NTM, the increase in cost was at rate that exceeded
healthcare inflation. For TB, this increase was at a lower rate than
inflation, which arguably represents a decline. Also identified in this study
were the unique demographic features of disease. For example, the
strong correlation between NTM and the elderly was observed, which is
concerning given the aging population structure of the US. As the large
number of baby boomers enter their final years, the incidence of NTM is
likely to demonstrate amplified increases, which could have a profound
impact on healthcare costs.
For policy makers, this study has several important implications.
First and foremost, NTM has been established as an emerging public
health problem for which little is known. The epidemiology of NTM has not
been widely measured on a national or global scale. The few data that
exist are limited to select countries and care settings. Even piecing
together currently available knowledge does not begin to capture the
actual distribution of NTM disease on a national or global scale. As a
result, the scope of the problem is not understood. Further, many
scientific aspects of the disease remain unknown. Current literature has
described various aspects of disease. First, risk groups have been well
described. Also, the presence of infectious species in environmental

157

samples, water, and the food have been documented. Further, NTM has
found to be transmitted person to person in certain situations. Despite
ongoing research, little is known about how transmission occurs.
Therefore, the policy implications for NTM as a public health challenge
represent a different type of approach traditionally undertaken by public
health. With new diseases come new challenges that rival in importance
to previous and successful public health policy. The ability of public health
to recognize emerging problems that may not resemble those of centuries
past represents a true test of policy makers in their ability to recognize and
address public health challenges in all shapes and sizes.
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